Document:

<PAGE>
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                   EXHIBIT 10.17

                                LICENSE AGREEMENT

      THIS LICENSE AGREEMENT ("Agreement"), effective as of July 1, 2001
("Effective Date"), is by and between the following parties:

CHUGAI DIAGNOSTICS SCIENCE CO., LTD., a corporation duly organized under the
laws of Japan, having a principal place of business at 41-8, Takada 3 Chome,
Toshima-Ku, Tokyo 171-8545, Japan ("CDS"), and

GEN-PROBE INCORPORATED, a Delaware corporation, having its principal place of
business at 10210 Genetic Center Drive, San Diego, California 92121-4362
("GEN-PROBE").

                                    PREAMBLE

      A. GEN-PROBE has developed proprietary technology relative to the
performance of diagnostic assays based on genetic probe technology for the
detection of agents causing infectious diseases, including viruses, and for the
detection of cancer and has the right to grant licenses to and under that
certain technology described and claimed in the Gen-Probe Patent Rights as
defined below.

      B. CDS desires to obtain a license from GEN-PROBE to practice the
inventions described in the Gen-Probe Patent Rights as defined below, and to
make, have made, use, sell or offer for sale Licensed Products, Future Licensed
Products and Licensed Methods as defined below, and GEN-PROBE is willing to
grant such a license on the terms and subject to the conditions provided herein.

      NOW, THEREFORE, in consideration of the mutual covenants set forth in this
Agreement, the parties hereby agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

      For purposes of this Agreement, the terms defined in this Article shall
have the meanings specified below:

      1.1 "Affiliate" shall mean a corporation or other legal entity that is
controlling or controlled by a Party. For purposes of this definition, "control"
means the ownership, directly or indirectly, of more than fifty percent (50%) of
the outstanding equity securities of a corporation which are entitled to vote in
the election of directors or a more than fifty percent (50%) interest in the net
assets or profits of an entity which is not a corporation.

                                       1
<PAGE>
      1.2 "Calendar Year" shall mean any calendar year commencing on January 1
and ending on December 31; provided, however that the 2001 Calendar Year shall
be the period commencing on the Effective Date and ending on December 31, 2001.

      1.3 "Confidential Information" shall mean all information and materials,
patentable or otherwise, of a Party which are not generally known or available,
are treated as private and confidential by the disclosing Party and are
disclosed by or on behalf of such Party to the other Party pursuant to this
Agreement, including, but not limited to, formulations, techniques, methodology,
equipment, data, reports, customer lists, pre-clinical and clinical trials and
the results thereof, sources of supply, patent positioning and business plans,
including any negative developments, whether or not related to this Agreement.

      1.4 "Dispute" shall mean any controversy or claim relating to, arising out
of or in any way connected to any provision of this Agreement.

      1.5 "Effective Date" shall mean the date first set forth above.

      1.6 "Exchange Rate" shall mean, with respect to any amount to be converted
from a foreign currency to U.S. dollars hereunder, Sumitomo Mitsui Banking
Corporation's TTS rate on the last Japanese business day of the Semi-Annual
Period preceding the applicable Semi-Annual Period.

      1.7 "Field" shall mean the field of diagnostics, including but not limited
to human, animal and environmental diagnostics and food testing and of
investigational use only (IUO) applications. The "Field" specifically does not
include nucleic acid probe based testing of human blood, plasma or other blood
products intended for direct transfusion or administration to humans. The
"Field" also does not include nucleic acid probe based testing for infectious
agents in blood in connection with organ transplants.

      1.8 "First Commercial Sale" shall mean the first sale by CDS of any
Licensed Product, Future Licensed Product to be defined in Section 3.1, or
Licensed Method for value and not for demonstration, testing or promotional
purposes.

      1.9 "Gen-Probe Patent Rights" shall mean (a) the Japanese patents, patent
applications and international applications, to the extent they enter the
national stage in Japan, identified in Exhibit "A" to this Agreement; (b) all
patents that have issued or in the future issue, that are derived from or are
related to, by priority, in whole or in part, all patents, patent applications
and international applications identified in Exhibit A to this Agreement,
including without limitation utility model and design patents and certificates
of invention; and (c) all reissues, reexaminations, renewals and extensions,
continuations, continuations-in-part and divisionals, claiming priority from the
Japanese patent applications,

                                       2
<PAGE>
patents and international applications, to the extent they enter the national
stage in Japan, identified in Exhibit A. In each case, the Gen-Probe Patent
Rights include only those patents, patent applications and international
applications, to the extent they enter the national stage in Japan, for which
Gen-Probe has the legal right to grant licenses, immunities or other rights
thereunder. Notwithstanding the above, in the future at GEN-PROBE's sole
discretion, GEN-PROBE may offer to add its totally new patents and patent
applications to the Exhibit A in exchange for a reasonable compensation to be
mutually agreed upon.

      1.10 "Licensed Method" shall mean any method, the use or practice of which
would constitute, but for the license granted herein, an infringement of any
issued Valid Claim within the Gen-Probe Patent Rights; provided, however, that
Licensed Methods shall never include any method directed to the detection of any
target or marker that is excluded from Future Licensed Products under Section
3.1. In the event that CDS (or its Affiliate(s)) invoices third parties for
CDS's performance of a Licensed Method used in conjunction with a Licensed
Product or Future Licensed Product, then Net Sales (as defined in Section 1.12,
below) shall include an amount equal to the average per unit Net Sales
attributed to the Licensed Method multiplied by the number of such Licensed
Methods performed by CDS (or its Affiliate(s)) during the Semi-Annual Period. If
such Licensed Product or Future Licensed Product is not sold to third parties
for commercial use during such Semi-Annual Period, a reasonable apportionment
shall be made of the gross amount invoiced for performance of the Licensed
Method between the value of the Licensed Product or Future Licensed Product per
se and the value of the laboratory services associated therewith, taking into
account the average selling prices of products similar to the Licensed Products
or Future Licensed Products. Such apportionment shall be negotiated in good
faith between the Parties.

      1.11 "Licensed Product" shall mean any already developed product or
product in development as of the Effective Date of this Agreement including the
products listed on Exhibit B to this Agreement to the extent that it is:

            a. Any product that is specifically intended for use in practicing a
            Licensed Method;

            b. Any product that lacks a substantial use other than in practicing
            a Licensed Method; or

            c. Any product, the making, using, selling, or offering for sale of
            which would constitute, but for the license granted herein, an
            infringement of any issued Valid Claim within the Gen-Probe Patent
            Rights and/or patents on Derivative Inventions;

                                       3
<PAGE>
provided, however, that the products which CDS, as of the Effective Date,
distributes under the Distribution Agreement between GEN-PROBE and CDS dated
September 1, 1998, shall be excluded from the Licensed Product definition.

      1.12 "Net Sales" shall mean the aggregate amount of revenue in U.S.
Dollars (converted as necessary for sales made in a currency other than U.S.
Dollars into U.S. Dollars at the applicable Exchange Rate on the last business
day of such Semi-Annual Period in accordance with Section 1.6 above) received or
receivable by CDS and/or its Affiliates with respect to all Licensed Products,
Licensed Methods and Future Licensed Products sold during such Semi-Annual
Period, (for any Licensed Product, Licensed Method or Future Licensed Product
transferred for consideration other than cash, the sales price shall be deemed
to be the average price at which identical Licensed Products, Licensed Methods
or Future Licensed Products were sold by CDS or its Affiliates during such
Semi-Annual Period in "arms-length" transactions), less only the following:

                                     [***]

      1.13 "Party" or "Parties" means, in the singular, CDS or GEN-PROBE and in
the plural, CDS and GEN-PROBE.

      1.14 "Royalty Period" shall mean the Semi-Annual Period or partial
Semi-Annual Period, commencing with the Effective Date of this Agreement, and
each Semi-Annual Period thereafter.

      1.15 "Semi-Annual Period" shall mean, for each calendar year, the six
month period beginning on each January 1 or July 1 of such year, without regard
to whether such dates are otherwise business days.

                                       4

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

<PAGE>
      1.16 "Term" shall mean the term of this Agreement, consisting of the
period from the Effective Date until termination of this Agreement in accordance
with Article X hereof.

      1.17 "Territory" shall mean the country of Japan only.

      1.18 "United States" shall mean the United States of America, its
territories and possessions.

      1.19 "U.S. Dollar" shall mean the United States dollar. All references in
this Agreement to monetary amounts shall be to U.S. Dollars unless otherwise
stated.

      1.20 "Valid Claim" shall mean any claim of the patents included within the
Gen-Probe Patent Rights which either (a) is included in an issued patent that
has not been held unenforceable or invalid by any agency or court of competent
jurisdiction in any unappealable or unappealed decision or (b) remains pending
in a patent application that has not been abandoned or finally rejected without
the possibility of appeal or refiling.

                                   ARTICLE II
                                 GRANT OF RIGHTS

      2.1 License Grant. Subject to the terms and conditions of this Agreement,
GEN-PROBE hereby grants CDS, and CDS hereby accepts a non-exclusive,
non-transferable, royalty-bearing license in the Territory under the Gen-Probe
Patent Rights to develop, make, have made, use, offer for sale, sell and have
sold, Licensed Products in the Field, Future Licensed Products pursuant to
Section 3.1 and to practice Licensed Methods in the Field.

      2.2 Initial License Fee. CDS agrees to pay a one-time license fee of [***]
to GEN-PROBE for the rights granted from the Effective Date through termination.
Said payment shall be made within sixty (60) days of the execution of this
Agreement.

      2.3 Licensed Products Distribution Option. If CDS completes development of
a Licensed Product, GEN-PROBE shall have an option to distribute such Product
outside the Territory on reasonable commercial terms. Following notification by
CDS of submission to the Ministry of Health, Labor and Welfare or equivalent
government authority of an application for approval of a Licensed Product,
GEN-PROBE shall have one hundred and twenty (120) days to exercise its option.
If GEN-PROBE exercises its option to distribute a Licensed Product outside the
Territory, the Parties shall negotiate in good faith the reasonable commercial
terms of such distribution agreement. Should GEN-PROBE elect not to exercise its
option for distribution rights outside the Territory, CDS may present to
GEN-PROBE for written approval a third party candidate for

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       5
<PAGE>
the distribution rights on the same or less beneficial terms and conditions as
those offered to GEN-PROBE. CDS agrees they shall not select any third party
candidate that would compete with GEN-PROBE products or with GEN-PROBE partners'
or collaborators' products in the nucleic acid testing area. If GEN-PROBE
declines to exercise this option during the one hundred twenty (120) days and
CDS later proposes a distribution agreement with a third party under more
favorable terms and conditions than were originally offered to GEN-PROBE, CDS
must return to GEN-PROBE and offer the distribution rights under the more
favorable terms and conditions to GEN-PROBE.

      2.4 Limitation of Rights. CDS acknowledges that its rights under the
Gen-Probe Patent Rights are limited to those expressly granted herein and that
CDS is not granted the right to develop, make, use, sell, transfer or otherwise
make available to Third Parties any products other than Licensed Products, or to
make, use or sell Licensed Products outside the Field or outside the Territory
(except that CDS shall have the right to sell Licensed Products and/or Future
Licensed Products, pursuant to the terms of this Agreement, for resale outside
the Territory pursuant to Section 2.3 and Section 3.4).

      2.5 Sublicensing. CDS shall have the right to sublicense to its Affiliates
the rights granted by GEN-PROBE to CDS under this Article II. CDS shall not have
the right to grant a sublicense to any party other than an Affiliate without the
prior written consent of GEN-PROBE.

      2.6 Assignment. Neither Party to this Agreement shall have the right to
assign, delegate, mortgage, pledge, hypothecate, sublicense or otherwise
transfer any rights or obligations under this Agreement without the prior
written consent of the other Party. Any such purported transfer without such
prior written consent shall be deemed void and without effect. For purposes of
this Agreement, "assignment" shall include (i) the transfer of substantially all
of the assets of a Party, even if this Agreement is specifically excluded from
such transfer and (ii) any change in the ultimate beneficial control of a Party.
CDS's rights under this Agreement shall terminate upon any merger,
consolidation, or similar change in corporate structure to which GEN-PROBE has
not consented in writing. Notwithstanding the foregoing, either Party may assign
and transfer this Agreement, including all its rights and obligations hereunder,
to any Affiliate of such Party, provided that such assignment shall not relieve
the assigning Party of its obligations hereunder. Notwithstanding any of the
foregoing, GEN-PROBE may assign and transfer this Agreement, including all its
rights and obligation hereunder, to any party succeeding to all its business. In
addition, GEN-PROBE may assign or transfer its right to receive payments
hereunder upon reasonable prior written notice to CDS.

      2.7 Ownership. GEN-PROBE shall retain the unrestricted right to use,
and/or license for use, for any purpose whatsoever, the property that is the
subject of this Agreement, inside or outside the Field. Except for the licenses

                                       6
<PAGE>
expressly granted under Section 2.1, no right, title, or interest in any
discovery, invention or other technology, data or information (or any patent,
copyright, trademark, or other intellectual property rights therein) of
GEN-PROBE shall pass to CDS under this Agreement. GEN-PROBE shall not be under
any obligation to grant to CDS any additional rights, other than those granted
by Section 2.1, in any patent, copyright, trademark, or other intellectual
property, nor shall GEN-PROBE be restricted with respect thereto.

      2.8 Limitations. Nothing in this Agreement shall be interpreted as giving
CDS the right to analyze, dissect, or disassemble any instrument, reagent,
component, object, software or other property of GEN-PROBE provided under the
terms of this Agreement, and which is not properly available from other sources
which have the right to transfer such property and authorize such activity, in
order to circumvent the need for a license of the technology reflected therein.
The licenses granted hereunder do not include a license for research and
development activities which are intended to identify means by which the need
for the license can be avoided.

      2.9 Recognition of Stanford and Organon Teknika Agreements. The rights
granted to CDS by GEN-PROBE hereunder are subject to the following:

      Stanford Agreement. The patent rights designated as "Selective
      Amplification", U.S. Patent No. 5,437,990 are sublicensed to CDS having
      its principal place of business at 41-8 Takada 3-Chome, Toshima-Ku, Tokyo
      171-8545, Japan by GEN-PROBE under the terms of a co-exclusive license
      agreement (the "Stanford Agreement") effective April 27, 1997 between
      GEN-PROBE and The Board of Trustees of the Leland Stanford Junior
      University, Palo Alto, California ("Stanford"). Under the terms of the
      Stanford Agreement, certain provisions as set forth in Exhibit E, attached
      hereto, are incorporated into this Agreement by reference.

      Teknika Agreement. GEN-PROBE is a party to a non-assertion agreement
      effective February 7, 1997 (the "Teknika Agreement") with Organon Teknika
      B.V., having a place of business at Boseind 15, 5281 RM Boxtel, The
      Netherlands ("Teknika"), which agreement grants certain rights and imposes
      certain conditions with respect to the transcription-based amplification
      patent rights owned or licensed by GEN-PROBE. CDS agrees, at the request
      of Teknika, to permit and to cooperate fully with an annual review of its
      manufacturing records (and such other records as may be required) by an
      impartial, technically qualified third party to verify compliance with the
      provisions of Section 3.3 of the Teknika Agreement. Selection of such
      third party shall be subject to the approval of CDS, such approval to be
      not unreasonably withheld. The results of such a review as provided to
      Teknika will consist solely of a finding of compliance or non-compliance.
      The cost of such review shall be borne by Teknika and shall not be
      unreasonably burdensome for CDS.

                                       7
<PAGE>
      CONTINUATION OF RIGHTS. In the event the Stanford Agreement or Teknika
      Agreement is terminated for any reason, the rights under such agreements
      which are granted by GEN-PROBE to CDS under this Agreement, as applicable,
      may be continued with Stanford and/or Teknika, as applicable, provided
      that certain conditions precedent, as set forth in Exhibit E, shall have
      been fulfilled.

      2.10 Notification of Future Licenses Granted. GEN-PROBE agrees to notify
CDS prior to any public announcement being made, in the event that GEN-PROBE
grants to a third party a license in Japan for the Gen-Probe Patent Rights.

                                   ARTICLE III
                                 FUTURE PRODUCTS

      3.1 Development of Future Licensed Products. Subject to all of the terms
and constraints of the license grant of Section 2.1, CDS shall have the right to
develop and include with the license granted hereunder diagnostic assays and
assays for investigational use only (IUO) applications in addition to those
identified on Exhibit B (such additional assays to be referred to as the "Future
Licensed Products"). CDS shall exercise its right to designate Future Licensed
Products by providing GEN-PROBE with written notice of such designation. Future
Licensed Products under this Agreement and the license granted to CDS under
Section 2.1, shall not, under any circumstances, include any product, regardless
of instrument platform, directed to the markers or disease targets identified on
Exhibit C which have been exclusively licensed to Bayer Corporation pursuant to
the provisions of a June 11, 1998 agreement between GEN-PROBE and Chiron (a copy
of which has been made available to CDS). Additionally, Future Licensed Products
under this Agreement and the license granted to CDS under Section 2.1, shall not
under any circumstance include any product, regardless of instrument platform,
directed to a marker or disease target for which GEN-PROBE has given or received
a "Blocking Notice" pursuant to Section 4.3.7 of the June 11, 1998 agreement
between GEN-PROBE and Chiron (a copy of which has been made available to CDS).
Additionally, Future Licensed Products and the license granted to CDS under
Section 2.1 shall not include any product, regardless of instrument platform,
directed to the markers or disease targets identified on Exhibit D which are
targets for current GEN-PROBE products. Additionally, Future Licensed Products
and the license granted to CDS under Section 2.1 shall not under any
circumstances include any product directed to a marker or disease target for
which GEN-PROBE can demonstrate by reasonably satisfactory evidence that, prior
to the time it received CDS's designation of such assay, GEN-PROBE had completed
the Design Review Process Phase 1 on a probe based assay. If GEN-PROBE receives
a designation from CDS for a Future Licensed Product that is precluded by this
Section, it will notify CDS in

                                       8
<PAGE>
writing within thirty (30) days and provide reasonably satisfactory
documentation to support the exclusion of the proposed probe based assay from
the license granted hereunder.

      3.2 Termination of License. The license granted under this Agreement for
each Future Licensed Product for commercial sale shall terminate unless CDS
begins active development of such Future Licensed Product within six (6) months
of the date of the written notice by CDS to GEN-PROBE under Section 3.1 above,
and CDS submits an application of approval of such Future Licensed Product to
the Ministry of Health, Labor and Welfare or equivalent government authorities
within four (4) years of the date of the written notice by CDS to GEN-PROBE
under Section 3.1 above. The license granted under this Agreement for each
Future Licensed Product for investigational use only ("IUO") shall terminate
unless CDS begins active development of such Future Licensed Product within six
(6) months of the date of the written notice by CDS to GEN-PROBE under Section
3.1 above and CDS accomplishes the first commercial sale of the IUO Future
Licensed Product within eighteen (18) months of the date of the written notice
by CDS to GEN-PROBE. Notwithstanding the above, each period of four (4) years
and eighteen (18) months specified above may be extended upon mutual written
consent.

      3.3 Development Support and Funding. All development work for all Licensed
Products and Future Licensed Products shall be the sole responsibility of CDS.
In GEN-PROBE's sole discretion, GEN-PROBE may, at the request and cost of CDS,
provide CDS with technical information, materials or technical training pursuant
to any of GEN-PROBE's new technologies or inventions, provided that such a
transfer is permitted by laws and regulations.

      3.4 Future Licensed Product Distribution Option. If CDS develops a Future
Licensed Product, GEN-PROBE shall have an option to distribute such Product
outside the Territory on reasonable commercial terms. Following notification by
CDS of submission to the Ministry of Health, Labor and Welfare or equivalent
government authorities of an application for approval of a Future Licensed
Product, GEN-PROBE shall have one hundred and twenty (120) days to exercise its
option. If GEN-PROBE exercises its option to distribute a Future Licensed
Product outside the Territory, the Parties shall negotiate in good faith the
reasonable commercial terms of such distribution agreement. Should GEN-PROBE
elect not to exercise its option for distribution rights outside the Territory,
CDS may present to GEN-PROBE for written approval a third party candidate for
the distribution rights on the same or less beneficial terms and conditions as
those offered to GEN-PROBE. CDS agrees they shall not select any third party
candidate that would compete with GEN-PROBE products or with GEN-PROBE partners'
products in the nucleic acid testing area. If GEN-PROBE declines to exercise its
option during the 120 days and CDS later proposes a distribution agreement with
a third party under more favorable terms and conditions than were originally
offered to GEN-PROBE, CDS must return to GEN-PROBE and

                                       9
<PAGE>
offer the distribution rights under the more favorable terms and conditions to
GEN-PROBE. GEN-PROBE approval shall not be unreasonably withheld.

      3.5 Coordination. CDS and GEN-PROBE will meet at least semiannually to
provide updates on product development progress by the Parties, including but
not limited to: updates on patent status concerning Gen-Probe Patent Rights and
Derivative Inventions; business strategies pertaining to this License and Future
Licensed Products in the Territory. CDS and GEN-PROBE may also discuss and
consider the potential for collaboration or co-development activities in areas
of mutual interest and benefit: including but not limited to, CDS suggestions
for potential third party sub-licensees. Any activities outside the provisions
of this Agreement shall be at GEN-PROBE's sole discretion.

                                   ARTICLE IV
                                    ROYALTIES

      4.1 Royalty Payment for Past Licensed Sales. CDS agrees to pay GEN-PROBE
the amount of [***] as royalty payment for
sales of CDS's hepatitis B virus ("HBV") product in the period from product
launch (July, 1998) to the Effective Date of this Agreement. Said payment shall
be made in U.S. Dollars within thirty (30) days of the execution of this
Agreement. Beginning with the Effective Date of this Agreement, royalty payments
for the CDS HBV product shall be governed by this Agreement.

      4.2 Percentage Royalties. CDS agrees to pay GEN-PROBE royalties on Net
Sales as set forth herein. The amount of royalties payable under this Section
4.2 shall be determined on a Semi-Annual Period basis and, for any Semi-Annual
Period, such amount shall be calculated by taking (A) the Net Sales for such
Semi-Annual Period of all the Licensed Products and Future Licensed Products,
multiplied by (B) the Applicable Royalty Rate described below.

      4.3 Applicable Royalty Rate:

      The "Applicable Royalty Rate" shall be calculated as follows:

<TABLE>
<CAPTION>
      Applicable Rate   Portion of Total Annual Net Sales:
<S>                     <C>
      [***]             Less than or equal to $5 million
      [***]             > $5 million and less than or equal to $10 million
      [***]             > $10 million and less than or equal to $15 million
      [***]             > $15 million and less than or equal to $20 million
      [***]             > $20 million
</TABLE>

      [***]

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

                                       10
<PAGE>
      [***]

      4.4 Royalty Payments. The percentage royalty accruing to GEN-PROBE under
this Agreement shall be paid by CDS on a Semi-Annual Period basis beginning the
Semi-Annual Period in which a First Commercial Sale occurs. Payments shall be
made within forty-five (45) days of the end of each such Royalty Period. All
amounts payable to GEN-PROBE under this Section will first be calculated in the
currency of sale and then converted into U.S. dollars in accordance with Section
1.6 and, to the extent permitted by applicable law, international trade
convention and government regulations, such amounts shall be paid without any
deduction for withholding taxes, value-added taxes, collection fees, exchange
fees, bank transfer charges any other charges applicable to such payments,
except where such withholding by CDS is required by law, international trade
convention and government regulations. Payments shall be made by CDS to the
address set forth in this Agreement for GEN-PROBE, or in such other manner as
may be reasonably directed from time to time by GEN-PROBE.

      4.5 Pricing. CDS shall have sole discretion in establishing prices for
Licensed Products and Future Licensed Products based upon prevailing market
conditions, competitive factors and other commercial considerations it
reasonably deems relevant. Royalties payable under this Agreement shall not be
reduced through sale of such Products in a manner as to serve as a "loss
leader". Royalties payable under this Agreement shall not be reduced through
marketing of Licensed Products and Future Licensed Products, associated
instrumentation, or other products and services in such a manner as to distort
the relative value of the Licensed Products or Future Licensed Products in
relation to the cost or value of the instrument or other products and services,
when considered in light of the primary marketing practices within the clinical
diagnostic industry (or other relevant industry, if applicable).

      4.6 Taxes. In the event that CDS is required to withhold taxes imposed
upon GEN-PROBE for any payment under this Agreement by virtue of the laws or
governmental regulations of a country in which Licensed Products or Future
Licensed Products are sold or Licensed Methods are practiced, then such payments
will be made by CDS on behalf of GEN-PROBE by deducting from the payment due
GEN-PROBE and remitting such taxes to the proper authorities on a timely basis,
provided that CDS supplies GEN-PROBE with official documentation and/or tax
receipt on such withholdings supporting such taxes and such payments as may be
required by GEN-PROBE for its tax records.

      4.7 Royalty Reports. A report containing the following information shall
accompany each royalty payment:

                                       11

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

<PAGE>
            A. Gross sales of Licensed Products and Future Licensed Products
            made by CDS and its Affiliates during the applicable Royalty Period;

            b. Calculation of Net Sales for the applicable Royalty Period;

            c. Total Net Sales in U.S. dollars for the applicable Royalty
            Period, together with the exchange rates used for conversion; and,

            d. Calculation of the royalty amount payable to GEN-PROBE for the
            applicable Royalty Period.

All such reports shall be maintained in confidence by GEN-PROBE. If no royalties
or other payments are due to GEN-PROBE for any Semi-Annual Period, the report
shall so state.

      4.8 Records. CDS shall keep, and shall require that its Affiliates keep,
for a period of not less than three (3) years after each Calendar Year,
complete, true and accurate books of account and other records containing all
information and data which may be necessary to ascertain and verify the amount
of royalties payable hereunder for such Calendar Year, including, without
limitation, detailed backup for the computations of Net Sales which records
shall contain sufficient information to permit GEN-PROBE to confirm the accuracy
of any reports delivered to GEN-PROBE in accordance with Section 4.7. During the
term of this Agreement and for a period of three (3) years thereafter, GEN-PROBE
shall have the right from time to time (not to exceed twice during each Calendar
Year) to inspect, at reasonable times and under reasonable conditions, the books
and records of CDS containing the information referred to in this Section.

      4.9 Late Payments. Any payments by CDS that are not paid on or before the
date such payments are due under this Agreement shall bear interest charges at
the rate of one percent (1%) per month. The interest shall be one percent (1%)
for the first one to thirty-one days and shall be prorated on a daily basis
thereafter. The interest shall be calculated from the date the payment was due
to GEN-PROBE until actually received by GEN-PROBE.

      4.10 Third Party Royalties. CDS will be solely responsible for payment of
all royalties due to third parties as a result of CDS's development,
manufacture, use, or sale of any Licensed Products, Future Licensed Products or
Licensed Methods. GEN-PROBE agrees to provide commercially reasonable assistance
to CDS in their efforts to obtain third party licenses deemed necessary by CDS,
which third parties are listed on Exhibit F hereto.

                                       12
<PAGE>
                                    ARTICLE V
                                  INFRINGEMENT

      5.1 Infringement by Third Parties.

            (a) If CDS becomes aware of any known or suspected infringement by a
third party on any Gen-Probe Patent Rights or copyrights, or any unauthorized
use or misappropriation of know-how, Confidential Information or other
proprietary rights in any way pertaining to the Gen-Probe Patent Rights, CDS
shall notify GEN-PROBE, in writing, within two (2) weeks of learning of such
infringement and shall provide all available supporting information known to CDS
regarding any such infringement, unauthorized use or misappropriation.

            (b) If GEN-PROBE, at its own expense, commences a suit under this
Section, CDS shall provide reasonable cooperation and assistance to GEN-PROBE in
connection with any such suit, without any charge therefor other than reasonable
out-of-pocket expenses.

            (c) In the event GEN-PROBE commences a suit under this Section,
GEN-PROBE may require CDS to join in such suit as a party, but CDS shall have no
obligation to participate in the litigation except to the extent action is
required of a named party to the suit. If CDS is required to join in any such
suit, CDS shall have the right, at its sole expense, to participate and be
represented in any such suit by its own counsel, which counsel shall be
reasonably acceptable to GEN-PROBE. In the event the Parties win a suit under
this Section and obtain damages from such third party, CDS shall be entitled to
be reimbursed its pro rata share of any such award up to the amount of CDS's
total costs for the suit.

      5.2 Alleged Infringement on Rights of Third Parties. In the event that any
third party makes a written claim or demand, or brings an action, suit or
proceeding, against either Party (or any of its Affiliates), alleging
infringement of such third party's patent rights or copyrights or unauthorized
use or misappropriation of its know-how, confidential information or other
proprietary rights, arising out of, or in connection with Gen-Probe Patent
Rights, such Party shall promptly notify (within two (2) weeks of receiving
notice of such claim) the other Party in writing, and provide copies of all
materials or papers received by or served on such claimed Party from or by such
third party. Each Party agrees to make available to the other Party, without
charge, its advice and assessment with respect to the technical merits of any
matter which is the subject of any such claim, demand, action, suit or
proceeding.

                                   ARTICLE VI
                                   INVENTIONS

                                       13
<PAGE>
      6.1 Derivative Inventions. The Parties acknowledge and agree that,
notwithstanding that only limited rights have been granted hereunder, certain
new technology may be discovered or invented by CDS through CDS's use of the
Gen-Probe Patent Rights or GEN-PROBE Confidential Information within the uses
and in the manner contemplated by this Agreement. Any discovery, invention or
improvement that is made by CDS as a result of access to GEN-PROBE Confidential
Information, or through the use of Gen-Probe Patent Rights as licensed under
this Agreement, and which is closely and fundamentally related to such Gen-Probe
Patent Rights, shall be referred to herein as a "Derivative Invention".

            a. When CDS recognizes that it has made a Derivative Invention
            subject to this Article, it shall promptly disclose that fact to
            GEN-PROBE.

            b. CDS shall own any Derivative Invention.

            c. CDS may use such Derivative Invention, together with the
            Gen-Probe Patent Rights licensed hereunder, for those uses and
            purposes which do not require any further license of the Gen-Probe
            Patent Rights other than that granted herein (it being the agreement
            of the Parties that there are no implied license rights created by
            this Agreement).

            d. CDS agrees not to assert its rights in a Derivative Invention in
            such a manner as would block or diminish GEN-PROBE's rights and the
            rights of GEN-PROBE's collaborators to practice the Gen-Probe Patent
            Rights with which the Derivative Invention was made.

            e. Upon request, CDS shall grant a non-exclusive license to
            GEN-PROBE to enable GEN-PROBE to make, use, sell, offer for sale,
            and import products which use or include the Derivative Invention
            outside the Territory. If a Derivative Invention is not patentable,
            or if the Derivative Invention does not have any substantial
            commercial use other than uses which would infringe the Gen-Probe
            Patent Rights which are the subject of this Agreement, then the
            non-exclusive license to be granted hereunder shall not be royalty
            bearing. If a Derivative Invention is patentable and has a
            substantial commercial use which would not infringe the Gen-Probe
            Patent Rights, then the non-exclusive license to be granted
            hereunder shall include commercially reasonable terms to be
            negotiated. The "commercially reasonable terms" referred to above
            shall give full recognition in favor of GEN-PROBE to the value of
            the Gen-Probe Patent Rights with which the Derivative Invention was
            made. The "commercially reasonable terms" shall also give full
            recognition, in favor of CDS, to the value of the inventive
            application contributed by CDS to the Gen-Probe Patent

                                       14
<PAGE>
            Rights. Nothing contained herein shall require CDS to license to
            GEN-PROBE any technology other than the Derivative Invention itself.

                                   ARTICLE VII
                          REPRESENTATION AND WARRANTIES

      7.1 Authorization. Each Party represents and warrants to the other that it
has the legal right and power to enter into this Agreement, to extend the rights
and licenses granted to the other in this Agreement, and to fully perform its
obligations hereunder, and that the performance of such obligations will not
conflict with its charter documents or any agreements, contracts, or other
arrangements to which it is a party.

      7.2 Gen-Probe Patent Rights. GEN-PROBE represents and warrants that it has
the full legal right and power to enter into obligations and grant the rights
and licenses set forth in this Agreement. GEN-PROBE shall be responsible for
effectuating the patent applications of the Gen-Probe Patent Rights and for
maintaining the filed patents of the Gen-Probe Patent Rights in effect and full
force during the Term of this Agreement.

      7.3 Disclaimer of Warranties. The license and rights herein are provided
WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY
OTHER WARRANTY, EXPRESS OR IMPLIED. GEN-PROBE MAKES NO REPRESENTATION OR
WARRANTY THAT THE LICENSED PRODUCTS OR LICENSED METHODS WILL NOT INFRINGE ANY
PATENT OR PROPRIETARY RIGHT OF OTHERS. CDS shall be solely responsible for
payment of all royalties due to any third parties in connection with CDS's
development, manufacture, use or sale of any Licensed Product.

      7.4 Limitation of Liability. IN NO EVENT WILL GEN-PROBE BE LIABLE FOR ANY
INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM CDS'S EXERCISE OF
THIS LICENSE OR ITS USE OF LICENSED PRODUCTS OR LICENSED METHODS.

                                  ARTICLE VIII
                                 CONFIDENTIALITY

      8.1 Treatment of Confidential Information. Each Party shall maintain the
Confidential Information of the other Party in confidence, and shall not
disclose, divulge or otherwise communicate such Confidential Information to
others, or use it for any purpose, except that each Party shall have the right
to disclose Confidential Information to its employees who have a need to know
such information in order to fulfill the objectives of this Agreement. Each
Party hereby agrees to exercise its best efforts and precautions (at least the
same

                                       15
<PAGE>
degree of care that the Party uses to protect its own Confidential Information)
to prevent and restrain the unauthorized disclosure of such Confidential
Information by any of its directors, officers, employees, consultants,
subcontractors, agents and Affiliates which shall include obtaining appropriate
secrecy or confidentiality undertakings from such persons. Each Party shall be
responsible for any breach of any such undertakings by its employees, agents or
representative.

      8.2 Exceptions to Confidentiality

            8.2.1 The restrictions on disclosure and use set forth in Section
8.1 shall not apply:

            a.    To information which was generally available to the public at
                  the time of disclosure, or information which becomes available
                  to the public after disclosure by Disclosing Party other than
                  through fault of the Receiving Party.

            b.    To information which can be shown to have been already known
                  to the Receiving Party prior to its receipt from the
                  Disclosing Party.

            c.    To information which is obtained at any time lawfully from a
                  third party under circumstances permitting its use or
                  disclosure to others.

            d.    To information which is developed independently by Receiving
                  Party as evidenced by written records other than through
                  knowledge of the Confidential Information.

            e.    In any event, after the expiration of five (5) years from the
                  termination date of this Agreement.

            f.    To information required to be disclosed by the Receiving Party
                  to comply with a court or administrative order provided the
                  Receiving Party furnishes prompt notice (in no event more than
                  3 days) to Disclosing Party to enable it to resist such
                  disclosure.

            8.2.2 The foregoing exceptions to Confidential Information shall not
operate to exclude from Confidential Information any information that (i) is
merely embraced by more general information available on a nonconfidential basis
or, (ii) consists of a combination of features, each of which may be publicly
available, but wherein the combination itself and its principle of operation
constitute Confidential Information because they are not embraced by
corresponding information which is within one of the foregoing exceptions.

                                   ARTICLE IX

                                       16
<PAGE>
                                 INDEMNIFICATION

      9.1 Indemnification by CDS. CDS shall indemnify, defend, and hold harmless
GEN-PROBE and its Affiliates and their directors, officers, employees, and
agents and their respective successors, heirs and assigns (the "Indemnitees")
against any and all claims, suits, losses, liability, damages, or expenses
resulting from or arising out of CDS's exercise of the licensed rights granted
herein including any sale, manufacture or use of a Licensed Product or
performance of a Licensed Method (including reasonable attorney's fees and
expenses of litigation). This indemnification will include, but not be limited
to, any product liability.

      9.2 Notification. GEN-PROBE shall promptly notify CDS in writing of any
claim which GEN-PROBE believes it may have a right of indemnification under this
Agreement.

      9.3 Cooperation. GEN-PROBE will provide reasonable cooperation to CDS for
a claim, suit, loss or damage subject to Section 9.1.

                                    ARTICLE X
                              TERM AND TERMINATION

      10.1 Term. This Agreement shall commence on the Effective Date and shall
remain in effect for ten (10) years, unless earlier terminated as provided in
this Article X. Thereafter, this Agreement shall automatically renew for
consecutive one (1) year terms unless one Party gives notice to the other Party
of non-renewal ninety (90) days or more prior to the expiration date.

      10.2 Survival. Any termination of this Agreement shall not affect the
following:

            a. CDS's obligations that have accrued prior to termination;

            b. CDS's continuing obligation to indemnify GEN-PROBE; and

            c. GEN-PROBE's or CDS's continuing obligation to maintain the
            confidentiality of the terms of this Agreement and any Confidential
            Information received from the other Party pursuant to this
            Agreement.

      10.3 Material Breach By CDS. If CDS should violate or fail to perform any
material term or covenant of this Agreement, GEN-PROBE may give written notice
of such default ("Notice of Default") to CDS. If CDS should fail to take
appropriate steps to cure such default within sixty (60) days of the effective
date of such Notice of Default pursuant to the notice provisions of Section
14.11, GEN-PROBE shall have the right to terminate the license and rights
granted to

                                       17

<PAGE>
CDS hereunder by issuing a second written notice ("Notice of Termination") to
CDS. Thereafter, the license and rights previously granted to CDS shall
terminate automatically on the effective date of the Notice of Termination. Such
termination shall not relieve CDS of its obligation to pay any royalty or
license fees owing at the time of termination and shall not impair any accrued
right of GEN-PROBE.

      10.4 Material Breach by GEN-PROBE. If GEN-PROBE should violate or fail to
perform any material term or covenant of this Agreement, CDS may give written
notice of such default ("Notice of Default") to GEN-PROBE. If GEN-PROBE should
fail to take appropriate steps to cure such default within sixty (60) days of
the effective date of such Notice of Default pursuant to the notice provisions
of Section 14.11, CDS shall have the right to terminate the license by issuing a
second written notice ("Notice of Termination") to GEN-PROBE. Thereafter, the
license and rights shall terminate automatically on the effective date of the
Notice of Termination. Such termination shall not relieve CDS of its obligation
to pay any royalty or license fees owing at the time of termination and shall
allow CDS to continue to sell Licensed Product, Licensed Methods and Future
Licensed Products which CDS has in inventory for a period not to exceed six (6)
months after the effective date of the Notice of Termination. Any such sales
after the effective date of the Notice of Termination shall be subject to the
provisions of Article IV.

                                   ARTICLE XI
                                 PATENT MARKING

      If requested by GEN-PROBE, CDS agrees to mark all Licensed Products made,
used or sold under the terms of this Agreement, or their containers, with the
patent number or numbers of any applicable Gen-Probe Patent Rights practiced
thereby to the extent it is not prohibited by law.

                                   ARTICLE XII
                                     EXPORT

      12.1 Acknowledgment. The Parties acknowledge that the export of technical
data, materials or products is subject to the exporting Party receiving all
necessary export licenses and that the Parties cannot be responsible for any
delays attributable to export controls which are beyond the reasonable control
of either Party. Each Party covenants and agrees to comply with all applicable
treaties, laws, statutes, rules and regulations of their respective federal,
state or local governmental entity or instrumentality, including, without
limitation, GEN-PROBE's responsibility under the provisions of the United States
Export Administration Act of 1969, as amended, and all other applicable export
laws, restrictions and regulations of the Department of Commerce and the United
States Food and Drug Administration ("FDA") and CDS's responsibility under
Japanese import and export restrictions and requirements. The receiving Party

                                       18
<PAGE>
shall provide the exporting Party with any information, materials,
certifications of other documents which may be reasonably required in connection
with such export laws, restrictions and regulations.

      12.2 Written Assurance. Without limitation of the foregoing, and in
support of maintaining a general license for the export of technical data under
this Agreement, CDS agrees that the Gen-Probe Patent Rights are for use in Japan
only and will not be knowingly exported from Japan, directly or indirectly,
without CDS first obtaining written permission from GEN-PROBE for such export.
GEN-PROBE agrees that such permission shall include obtaining permission for
export (if required) from the United States Department of Commerce, the FDA
and/or other appropriate United States governmental agencies. CDS shall be
responsible for obtaining permission from any countries to which the export will
be made.

                                  ARTICLE XIII
                                   ARBITRATION

      In the event of any Dispute, the Parties shall seek to settle their
differences amicably between themselves, including entering into non-binding
mediation. Any unresolved dispute shall be resolved by final and binding
arbitration in accordance with this Article. Whenever a Party shall decide to
institute arbitration proceedings, it shall give written notice to that effect
to the other Party. The Party giving such notice shall refrain from instituting
the arbitration proceedings for a period of ten (10) days following such notice
to allow the Parties to attempt to resolve the dispute between them. If the
Parties are still unable to resolve the dispute, the Party giving notice may
institute the arbitration proceeding under the rules of Conciliation and
Arbitration of the International Chamber of Commerce as then in effect ("ICC
Rules"). Arbitration shall be held in New York, New York. The arbitration shall
be conducted before three arbitrators, with each Party to select one arbitrator
and with the third arbitrator to be appointed in accordance with ICC Rules. The
arbitrators shall undertake in writing as a condition of service to conduct
proceedings in a speedy and efficient manner, to render the award promptly after
the final arbitration hearing, and further shall confirm in writing to the
President of the Court of Arbitration of the International Chamber of Commerce
that such undertaking is being or has been fulfilled, or shall report the
reasons for any failure of fulfillment, as a condition for any application for
fees. If so requested by either Party, preparation of any Terms of Reference
referred to in ICC Rules shall be waived and the matters in dispute shall be
determined by the arbitrators based on the timely submissions of the Parties.
The arbitrators shall not have the power to award punitive damages or any award
of multiple damages under this Agreement and such awards are expressly
prohibited. Any arbitration award shall be by majority vote and shall be final
and binding on the Parties. Judgment on the award may be entered in any court
having jurisdiction. Except to the extent entry of judgment and any subsequent
enforcement may require disclosure, all matters relating to the

                                       19
<PAGE>
arbitration, including the award, shall be held in confidence by the Parties.
Nothing contained in this Article shall prevent either Party from seeking
temporary restraining orders, injunctions or such other relief in any court of
competent jurisdiction.

                                   ARTICLE XIV
                                  MISCELLANEOUS

      14.1 Force Majeure. Each of the Parties hereto shall be excused from the
performance of its obligations hereunder in the event performance of this
Agreement is prevented by force majeure and such excuse shall continue as long
as the condition constituting such force majeure continues, plus thirty (30)
days after the termination of such condition. For purposes of this Agreement,
force majeure is defined as follows:

                  Causes beyond the control of CDS or GEN-PROBE, including acts
            of God; war; any regulations, acts, rules, orders, proclamations,
            requirements or laws of any government; civil commotion; strike,
            lockout or other industrial dispute; destruction of production
            facilities or material by fire, water, earthquake or storm; plant
            breakdown or failure of equipment; inability to obtain equipment
            and/or supplies; epidemics; failure of public utilities or common
            carriers; or by any circumstances whatsoever beyond a Party's
            reasonable control.

      14.2 Specific Performance and Injunction. The Parties agree that
irreparable damage will occur in the event that the provisions of Article VIII
are not specifically enforced. In the event of a breach or threatened breach of
any such provisions, CDS agrees that GEN-PROBE shall, in addition to all other
remedies, be entitled to temporary or permanent injunction, without showing any
actual damage or that monetary damages would not provide an adequate remedy and
without the necessity of posting any bond, and/or a decree for specific
performance, in accordance with the provisions hereof.

      14.3 Governing Law. This Agreement will be construed and governed by the
laws of the State of New York, without giving effect to conflict of law
provisions and excluding the United Nations Convention of Contracts for the
International Sale of Goods, except that any arbitration hereunder shall be
governed by Article XIII herein.

      14.4 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, and all of which
together shall be deemed to be one and the same instrument.

                                       20
<PAGE>
      14.5 No Third Party Benefits. Nothing in this Agreement, express or
implied, is intended to confer on any person other than the Parties hereto or
their permitted assigns, any benefits, rights or remedies.

      14.6 Registration. In the event that this Agreement is required to be
registered with any governmental authority in the Territory, CDS shall cause
such registration to be made and shall bear any expense or tax payable in
respect thereof.

      14.7 English Language. The official text of this Agreement shall be in the
English language, and such English text shall be controlling in all respects,
notwithstanding any translation hereof required under the laws and regulations
of the Territory. The Parties undertake to use the English language in respect
of all documents and communications contemplated herein, except where another
language must be used under the laws and regulations of the Territory. In any
such case, a certified English translation shall be supplied to the other Party
by the Party using such documents or making such communication.

      14.8 Headings. All headings in this Agreement are for convenience only and
shall not affect the meaning of any provision hereof.

      14.9 Binding Effect. This Agreement shall inure to the benefit of and be
binding upon the Parties and their respective lawful successors and assigns.

      14.10 Compliance With Law. Nothing in this Agreement shall be construed so
as to require the commission of any act contrary to law, and wherever there is
any conflict between any provision of this Agreement and any statute, law,
ordinance or treaty, the latter shall prevail, but in such event the affected
provisions of the Agreement shall be conformed and limited only to the extent
necessary to bring it within the applicable legal requirements.

      14.11 Notices. All notices, requests, demands and other communications
required or permitted to be given pursuant to this Agreement shall be in writing
and shall be deemed to have been duly given upon the date of receipt if
delivered by hand, recognized international overnight courier, confirmed
facsimile transmission, or registered or certified mail, return receipt
requested, postage prepaid to the following addresses or facsimile numbers:

     If to GEN-PROBE:                       If to CDS:
     Gen-Probe Incorporated                 Chugai Diagnostics Science Co., Ltd.
     10210 Genetic Center Drive             41-8, Takada 3 Chome, Toshima-Ku
     San Diego, California 92121-4362       Tokyo 171-8545
     U.S.A.                                 Japan
     Attn: President                        Attn: President
     Facsimile: (858) 410-8637              Facsimile: (0)3-3987-3516

                                       21
<PAGE>
Either Party may change its designated address and facsimile number by notice to
the other Party in the manner provided in this Section.

      14.12 Amendment and Waiver. This Agreement may be amended, supplemented,
or otherwise modified only by means of a written instrument signed by both
Parties. Any waiver of any rights or failure to act in a specific instance shall
relate only to such instance and shall not be construed as an agreement to waive
any rights or fail to act in any other instance, whether or not similar.

      14.13 Severability. In the event that any provision of this Agreement
shall, for any reason, be held to be invalid, or unenforceable in any respect,
such invalidity or unenforceability shall not affect any other provision hereof,
and the Parties shall negotiate in good faith to modify the Agreement to
preserve (to the extent possible) their original intent.

      14.14 Attorneys' Fees. If either Party hereto commences an arbitration or
other action against the other Party to enforce any of the terms hereof or
because of the breach by such other Party of any of the terms hereof, the
prevailing Party shall be entitled, in addition to any other relief granted, to
all actual out-of-pocket costs and expenses incurred by such prevailing Party in
connection with such action, including, without limitation, all reasonable
attorneys' fees, and a right to such costs and expenses shall be deemed to have
accrued upon the commencement of such action and shall be enforceable whether or
not such action is prosecuted to judgment.

      14.15 Entire Agreement. This Agreement constitutes the entire agreement
between the Parties with respect to the subject matter hereof and supersedes all
prior agreements or understandings between the Parties relating to the subject
matter hereof.

            (The remainder of this page is intentionally left blank)

                                       22
<PAGE>
      IN WITNESS WHEREOF, the undersigned have duly executed and delivered this
Agreement as a sealed instrument effective as of the date first above written.

GEN-PROBE INCORPORATED

By: /s/ Henry L. Nordhoff
    ____________________________
         Henry L. Nordhoff
         President & Chief Executive Officer

CHUGAI DIAGNOSTICS SCIENCE CO., LTD.

By: /s/ Haruo Kato
    _____________________________
         Haruo Kato
         President & Chief Executive Officer

                                       23
<PAGE>
                                    EXHIBIT A

                                GEN-PROBE PATENTS

[12 Pages of Gen-Probe Patents Deleted Pursuant to Confidential Treatment
Request]

                                       24

<PAGE>
                                    EXHIBIT B

                                LICENSED PRODUCTS

[***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       36
<PAGE>
                                    EXHIBIT C

                             EXCLUDED VIRAL TARGETS

EXCLUDED ASSAY TARGETS - EACH OF THE VIRUSES INCLUDED IN THIS LIST SHALL INCLUDE
MUTANTS, VARIANTS AND RELATED SUBTYPES

[***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       37
<PAGE>
                                    EXHIBIT D

                           EXISTING GEN-PROBE PRODUCTS

    AMPLIFIED CHLAMYDIA
    AMPLIFIED GONORRHOEAE
    DIRECT CHLAMYDIA-GONORRHOEAE
    AMPLIFIED MYCOBACTERIUM TUBERCULOSIS
    DIRECT MYCOBACTERIUM TUBERCULOSIS
    DIRECT GROUP A STREPTOCOCCUS
    ACCUPROBE CULTURE IDENTIFICATION MYCOBACTERIA
        MYCOBACTERUIM GORDONAE
        MYCOBACTERUIM KANSASII
        MYCOBACTERUIM TUBERCULOSIS COMPLEX
    ACCUPROBE CULTURE IDENTIFICATION FUNGI
        BLASTOMYCES DERMATITIDIS CULTURE
        COCCIDIOIDES IMMITIS CULTURE
        HISTOPLASMA CAPSULATUM CULTURE
    ACCUPROBE BACTERIA
        CAMPYLOBACTER CULTURE
        ENTEROCOCCUS CULTURE
        GROUP B STREPTOCOCCUS CULTURE
        HAEMOPHILUS INFLUENZAE CULTURE
        NEISSERIA GONORRHOEAE
        STREPTOCOCCUS PNEUMONIAE CULTURE
        STAPHYLOCOCCUS AUREUS CULTURE
        LISTERIA MONOCYTOGENES CULTURE
        GROUP A STREPTOCOCCUS CULTURE

                                       38

<PAGE>
                                    EXHIBIT E

              EXCERPTS OF STANFORD AND ORGANON TEKNIKA AGREEMENTS

ADDITIONAL CLAUSES RELATING TO THE STANFORD AGREEMENT

1. DEFINITIONS

      The following definitions shall apply within this Exhibit E. All other
defined terms shall have the meanings set forth elsewhere in the License
Agreement between GEN-PROBE and CDS of which this Exhibit E is a part.

      1.1 "Invention" shall mean all rights, titles and interest to the
technique of Selective Amplification of Target Polynucleotide Sequences, as
described in Stanford Docket S87-012 and pursuant to 35 U.S.C. 202, and any
Licensed Patent(s), as hereinafter defined, which may issue to such Invention.

      1.2 "Licensed Patent(s)" means US Patent No. 5,437,990 issued on August
1, 1995 and any Letters Patent issued upon Stanford's U.S. Patent Application,
Serial Number 080,479 filed July 31, 1987, including the information contained
in such application, with respect to the Invention, any foreign patents
corresponding thereto, and/or any divisions, continuations, or
continuations-in-part, or reissue thereof.

      1.3 "Licensed Product(s)" means any Licensed Product (as such term is
defined elsewhere in the License between GEN-PROBE and CDS of which this Exhibit
E is a part), the manufacture, use, or sale of which:

            (a)   Is covered by a valid claim of an issued, unexpired Licensed
                  Patent(s) directed to the Invention. A claim of an issued,
                  unexpired Licensed Patent(s) shall be presumed to be valid
                  unless and until it has been held to be invalid by a final
                  judgment of a court of competent jurisdiction from which no
                  appeal can be or is taken;
            (b)   Is covered by any claim being prosecuted in a pending
                  application directed to the Invention.

2. WARRANTY AND NEGATION OF WARRANTIES

      2.1 Nothing in this License is or shall be construed as:

            (a)   A warranty or representation by Stanford as to the validity or
                  scope of any Licensed Patent(s);
            (b)   A warranty or representation that anything made, used, sold,
                  or otherwise disposed of under any license granted in this

                                       39

<PAGE>
                  License is or will be free from of patents, copyrights, and
                  other rights of third parties;
            (c)   An obligation to bring or prosecute actions or suits against
                  third parties for infringement, except that Stanford, CDS, and
                  GEN-PROBE shall promptly inform each other of any suspected
                  infringement of any Licensed Patent(s) by another party; or
            (d)   Granting by implication, estoppel, or otherwise any licenses
                  under patents of Stanford or other persons other than Licensed
                  Patent(s), regardless of whether such patents are dominant or
                  subordinate to any Licensed Patent(s).

      2.2 EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, STANFORD MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OR MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE LICENSED PRODUCT(S)
WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD
PARTIES.

      3.  INDEMNITIES

      3.1 GEN-PROBE agrees to indemnify, hold harmless, and defend Stanford and
its trustees, officers, employees, students, and agents against any and all
claims for death, illness, personal injury, property damage, and improper
business practices arising out of the manufacture, use, sale, or other
disposition of Invention, Licensed Patent(s), or Licensed Product(s) by
GEN-PROBE, its sublicensees or their customers.

      3.2 CDS shall at all times comply, through insurance or self-insurance,
with all statutory workers' compensation and employer's liability requirements
covering any and all employees with respect to activities performed under this
License.

                                       40

<PAGE>
                                    EXHIBIT E

           ADDITIONAL CLAUSES IN THE STANFORD AND TEKNIKA AGREEMENTS
                    RELATING TO CONTINUATION OF SUBLICENSES

STANFORD AGREEMENT

      The Stanford Agreement sets forth the following terms and conditions
relating to the continuation of sublicenses following termination of the
Stanford Agreement:

      4.3.3 Upon termination of this Agreement for any cause, any sublicense
granted hereunder shall continue with STANFORD provided the sublicensee agrees
to thereafter assume the obligations of GEN-PROBE insofar as they correspond to
the scope of the sublicense.

TEKNIKA AGREEMENT

      The Teknika Agreement sets forth the following terms and conditions
relating to rights of Gen-Probe's Licensees should a breach by Gen-Probe
terminate its rights under the Teknika Agreement:

      10.3 Upon termination of this Agreement, as permitted by Section 10.2, the
non-breaching party shall grant direct immunity from legal action to Licensees
of the breaching party, under the terms and conditions set forth in this
Agreement, provided that:

            (a)   the non-breaching party shall have received express written
                  notice of the license granted to such Licensee prior to the
                  effective termination date of this Agreement;
            (b)   the Licensee expressly agreed in writing on or before the
                  ninetieth (90th) day prior to the effective termination date
                  of this Agreement to be bound by the terms and conditions of
                  this Agreement.

                                       41

<PAGE>
                                    EXHIBIT E

                           ADDITIONAL TEKNIKA CLAUSES

                   TRANSCRIPTION-BASED AMPLIFICATION VERSIONS

      "GEN-PROBE Version" shall mean transcription-based nucleic acid
amplification using reverse transcriptase, RNA polymerase and [***] wherein

          (a) the reverse transcriptase and RNase H activities are provided by
a [***]

          (b) said protein has a minimal reverse transcriptase activity of [***]
(where the unit definition and assay conditions are equivalent to those set
forth below); and,

          (c) the amplification reaction is performed at [***]

      "TEKNIKA Version" shall mean transcription-based nucleic acid
amplification using reverse transcriptase, RNA polymerase and [***] wherein:

          (a) [***]

          (b) [***] and

          (c) the amplification reaction is performed at  [***].

ENZYME ASSAYS

[***]

[***]

[***]

[***]

                                       42

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
[***]

Equivalent unit definitions and assay conditions may be substituted as long as
they produce results that may be quantitatively converted by established valid
procedures (e.g., multiplication by a conversion factor or by reference to a
standard curve) to the assay conditions and unit definitions set forth above.

For example, [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       43

<PAGE>
[***]

Data supporting equivalence of any substitutions must be made available for
inspection as set forth in Section 3.3 of this Agreement.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       44

<PAGE>
                                    EXHIBIT F

      Third Party Royalty Obligations For Gen-Probe Licensees

               [***]
                      [***] The royalty is calculated at the following rates:

               ANNUAL PRODUCT NET SALES       ROYALTY RATE

                                    [***]                 [***]

                      The royalty is calculated on the net sales revenue
                      received by the licensee.

                      An offset is applied to these royalties rates that allows
                      the deduction of other additional third party royalties
                      payable on the product. However the offset cannot reduce
                      the royalty rate payable to a rate that is less than [***]
                      of the applicable royalty. Consequently the lowest royalty
                      payable after third party deductions would be as follows:

               ANNUAL PRODUCT NET SALES       ROYALTY RATE

                                    [***]                 [***]

                        Royalty payments are made on a quarterly basis. All
                        GEN-PROBE licensees make payments to [***] through
                        GEN-PROBE. GEN-PROBE will provide CDS a quarterly
                        invoice for CDS's indirect royalty payment to [***].

        [***]
                        For all products that employ [***]. A royalty of [***]
                        on net sales revenue received by the licensee from
                        product sales of all products that employ [***]. All
                        GEN-PROBE licensees make payments to [***] through
                        GEN-PROBE. GEN-PROBE will provide CDS a quarterly
                        invoice for CDS's indirect royalty payment to [***].

        [***]
                        Gen-Probe pays [***] a royalty of [***] on end user
                        sales of

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       45

<PAGE>
all Gen-Probe [***].

                                     [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
                                       46<PAGE>
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                   EXHIBIT 10.18

                             DISTRIBUTION AGREEMENT

     This Distribution Agreement (hereinafter the "Agreement") is effective as
of September 1, 1998 (the "Effective Date"), by and between:

     GEN-PROBE INCORPORATED, a corporation duly organized under the laws of the
State of Delaware, United States of America, with its principal place of
business located at 10210 Genetic Center Drive, San Diego, California
92121-4362 USA ("GEN-PROBE") and,

     CHUGAI DIAGNOSTICS SCIENCE CO., LTD., a corporation duly organized under
the laws of Japan with its principal place of business located at 41-8, Takada
3-Chome, Toshima-ku, Tokyo, 171-8545 Japan ("CDS").

                                    RECITALS

     A.   GEN-PROBE is engaged in the business of developing and marketing
various in vitro diagnostic products which utilize genetic probe technology,
instruments, and products ancillary thereto;

     B.   CDS is engaged in the marketing and sale of in vitro diagnostic
products in Japan and has plans to expand its business to other countries in
Asia;

     C.   GEN-PROBE and Chugai Pharmaceutical Co., Ltd., a corporation duly
organized under the laws of Japan with its principal place of business located
at 1-9, Kyobashi 2-Chome, Chuo-ku, Tokyo, 104-8301 Japan ("CHUGAI"), entered
into a DISTRIBUTION AGREEMENT as of March 31, 1988, U.S.A. time, April 1, 1988,
Japenese time (the "Original Agreement");

     D.   CHUGAI transferred its diagnostic business to CDS as of October 1,
1997, and GEN-PROBE agreed to the assignment of the Original Agreement from
CHUGAI to CDS by letter of June 1, 1997;

     E.   GEN-PROBE wishes to have CDS act as its distributor for the sale of
certain of GEN-PROBE's in vitro diagnostic products, instruments and products
ancillary thereto in Japan and CDS wishes to act for GEN-PROBE in that capacity
under new terms of this Agreement;

     F.   GEN-PROBE and CDS agree to terminate the Original Agreement as of the
Effective Date, and replace the Original Agreement with this Agreement providing
such new terms and conditions.

     NOW THEREFORE, in consideration of the foregoing premises, the mutual
covenants and promises contained herein and other and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, GEN-PROBE and CDS
(collectively referred to as the "Parties") agree as follows:

<PAGE>

                                   ARTICLE I
                                  DEFINITIONS

     For the purpose of this Agreement, the terms set forth below shall have
the following meanings.

     1.01  "Affiliate" shall mean any corporation or other business entity
which controls, is controlled by or is under common control with GEN-PROBE or
CDS, as applicable. For purposes of this Section 1.01, control shall mean
direct or indirect ownership of more than 50% of the voting interest or income
interest in a corporation or entity, or such other relationship as, in fact,
constitutes actual control.

     1.02  "Calendar Quarter" shall mean, for each calendar year, the
three-month period beginning on January 1, April 1, July 1 or October 1 of such
year, without regard to whether such dates are business days.

     1.03  "Calendar Year" shall mean any calendar year commencing on January 1
and ending on December 31; provided, however that the 1998 Calendar Year shall
be the period commencing on September 1, 1998 and ending on December 31, 1998.

     1.04  "Clinical Microbiology and Laboratory Market" shall mean the market
for in vitro diagnostic products intended for use by large volume users such as
hospitals, reference laboratories, and public health services. It does not
include the market for in vitro diagnostic products intended for use in a
physician's office or for sale over-the-counter to the general public for
self-diagnosis.

     1.05  "Confidential Information" shall mean all information and materials,
patentable or otherwise, of a Party which are not generally known or available,
are treated as private and confidential by the disclosing Party and are
disclosed by or on behalf of such Party to the other Party pursuant to this
Agreement, including, but not limited to, formulations, techniques, methodology,
equipment, data, reports, market strategies and volumes, customer lists,
strategic planning, Know-How, preclinical and clinical trials and the results
thereof, sources of supply, patent positioning and business plans, including any
negative developments, whether or not related to this Agreement.

     1.06  "Copyrights" shall mean all copyrights of a Party (whether or not
registered).

     1.07  "Dispute" shall mean any controversy or claim relating to, arising
out of or in any way connected to any provision of this Agreement.

     1.08  "Effective Date" shall mean September 1, 1998.

     1.09  "Field" shall mean the field of human diagnostics.

     1.10  "Kit" shall mean, collectively, nucleic acid probes in combination
with all such other reagents and materials, not including Instruments or
Disposables, as are necessary to perform in vitro nucleic acid diagnostic
assays.

                                      -2-
<PAGE>

     1.11  "Know-How" shall means all information, patentable or otherwise, of
a Party that is not generally known that affords such Party a competitive
advantage with respect to its business.

     1.12  "Party" means CDS or GEN-PROBE; "Parties" shall mean GEN-PROBE and
CDS.

     1.13  "Patents" or "Patent Rights" shall mean patents and patent
applications of GEN-PROBE (whether solely owned or licensed to such Party).

     1.14  "Products" shall mean each, every, and all of the following:

     (i)       Kits for the performance of an in vitro diagnostic assay intended
               for use in the Clinical Microbiology and Laboratory Market (other
               than products developed by GEN-PROBE under agreement with third
               parties) identified in Exhibit A attached hereto, to the extent
               that such Kits are existing GEN-PROBE Products as of the
               Effective Date and GEN-PROBE has the right to market the Kits in
               the Territory;

     (ii)      the instruments described in Exhibit A ("Instruments");

     (iii)     the disposables described in Exhibits A ("Disposables");

     (iv)      any and all parts and components necessary for repair or
               replacement for any of the foregoing; and

     (v)       the reagents described in Exhibit A ("Reagent Components");

in each case, as the same may be modified and improved by GEN-PROBE from time
to time.

GEN-PROBE may not terminate the production of Products nor delete said Products
from the Exhibits without one hundred twenty (120) days prior written notice to
CDS. To the extent GEN-PROBE develops additional products, GEN-PROBE shall
propose in writing to include them within the definition of "Products" under
this Agreement. If GEN-PROBE makes such a proposal, CDS shall either accept or
reject the proposal in its entirety and as a whole in writing within sixty (60)
days. A corresponding adjustment to the Minimum Purchase Commitment under
Section 3.3 will be determined under mutual agreement before the new Product is
included within this Agreement. If GEN-PROBE finds that any product developed
by GEN-PROBE under any agreement with a Third Party can be sold in the
Territory, GEN-PROBE shall so notify CDS in writing.

     1.15.  "Sale Prices" shall mean the prices of the Products payable by CDS
to GEN-PROBE identified in Exhibit A attached hereto and incorporated herein by
this reference, as such prices may be changed from time to time pursuant to the
provisions of Section 4.2 hereof.

                                      -3-
<PAGE>
     1.16  "Technology" shall mean Patents and Copyrights as well as ideas,
inventions, Confidential Information, devices, trade secrets, procedures,
methods, information, data, studies, reports, processes, rights, manufacturing
information and Know-How.

     1.17  "Term" shall mean the period of this Agreement, consisting of the
period from the date hereof until termination of this Agreement in accordance
with Section 16.1 hereof.

     1.18  "Territory" shall mean Japan.

     1.19  "Third Party" shall mean, any person, corporation, or other business
entity that is not a Party or an Affiliate of a Party.

                                   ARTICLE II
                           APPOINTMENT OF DISTRIBUTOR

     2.1  Engagement.  GEN-PROBE hereby appoints CDS to act during the Term as
the sole and exclusive distributor of the Products in the Clinical Microbiology
and Laboratory Market in the Territory, and CDS hereby accepts such appointment.

     2.2  Limitations on Appointment.  CDS's right to distribute Products shall
not include the right to market products developed by GEN-PROBE whose main
application is intended to be in the physician's office market,
over-the-counter market, agricultural market, veterinary market, industrial
testing, food testing, or any therapeutic application. CDS's distribution
rights also do not include the right to market any products which have been
jointly developed with Third Parties.

     2.3  Duties of CDS.

          2.3.1  CDS shall at its own cost and expense distribute, sell, lease,
                 market, promote, service, support and maintain the Products in
                 the Territory. CDS shall arrange the terms of sale, including
                 price of the Products, between itself and its customers.

          2.3.2  CDS shall refrain from seeking customers outside the
                 Territory, from establishing any branch or from maintaining
                 any distribution depot relating to the Products. CDS further
                 agrees that it will make deliveries only within the Territory
                 and only to persons located within the Territory whom CDS
                 has no reason to believe will remove the Products outside
                 the Territory.

     2.4  Non-Competition.  As the sole and exclusive distributor of the
Products in the Territory, CDS will devote diligent efforts on a commercially
reasonable basis to marketing and promoting the Products in the Territory, and
to this end will not, either on its own behalf, or on behalf of any other
person or Affiliate, directly or indirectly, during the Term for any reason
manufacture, sell, distribute, or promote any products which might materially
compete with or adversely affect the sale of the Products.

                                      -4-

<PAGE>
     2.5  Exclusivity.  In consideration of GEN-PROBE's appointment of CDS as
its exclusive distributor for the Territory, CDS agrees that it will not
distribute for use in the Clinical Microbiology and Laboratory Market any other
DNA-probe-based product which performs the same function as any Product.

                                  ARTICLE III
                         PURCHASING/ORDERING PROCEDURES

     3.1  Purchases; Inventory.  CDS agrees during the Term to purchase from
GEN-PROBE, and GEN-PROBE agrees during the Term to use diligent efforts on a
commercially reasonable basis to supply CDS with, such quantities of the
Products as are necessary to maintain its inventory of the Products (including
spare parts and accessories) in a sufficient quantity to supply customer demand
for the Products within the Territory and to effectuate the purposes of this
Agreement.

     3.2  Orders.  CDS will purchase the Products by submitting written
purchase orders to GEN-PROBE at least sixty (60) days before the requested ship
date, containing valid purchase order numbers and signed by an authorized
representative of CDS. GEN-PROBE will acknowledge all accepted purchase orders
from CDS in writing. Such acknowledgment will verify pricing information and
specify estimated time of delivery. CDS shall use reasonable efforts to place
orders for the Products in an even and regular fashion to facilitate efficient
scheduling by GEN-PROBE of its production and GEN-PROBE shall use reasonable
efforts to accept such orders in such fashion.

     3.3  Minimum Purchase Commitments.  In consideration of the rights granted
to it under this Agreement, CDS guarantees that it will use its best commercial
efforts to promote and support (including making all reasonable investments in
facilities, personnel, equipment and materials) all listed Products and meet
the minimum purchases of Products in the quantities (the "Minimum Commitments")
and for the time periods (the "Performance Period") set forth in Exhibit B
hereto. Exhibit B will be amended from time to time in the case (as
contemplated in Section 1.14) of the addition or deletion of Products to
Exhibit A and/or the extension of the initial Term of this Agreement by mutual
agreement.

     In determining whether CDS has satisfied the Minimum Purchase Commitment
for any given Performance Period, each such Performance Period shall be treated
on a separate basis. Any purchases which exceed the minimum Purchase Commitment
in any Performance Period may not be applied to offset any deficiencies in the
Minimum Purchase Commitment for the prior or subsequent Performance Period, as
applicable. Only those purchase orders placed by CDS with GEN-PROBE during any
given Performance Period and for which delivery and payment therefor has been
made within such Performance Period shall be used to determine whether the
Minimum Purchase Commitment has been met.

     In the event that such purchase order during each Performance Period does
not reach the Minimum Purchase Commitment, CDS shall pay to GEN-PROBE sixty
percent (60%) of the difference between the actual purchase amount and the
Minimum Purchase Commitment.

                                      -5-
<PAGE>
     3.4  Forecasts. At least ninety (90) days prior to the start of each
calendar month, CDS will provide GEN-PROBE with a rolling product-specific
forecast of orders for such month and each of the succeeding five (5) months.
GEN-PROBE shall not be obligated to supply quantities of Products in excess of
such forecasts for any calendar month. Such forecast shall be provided on a
"best efforts" basis and shall not constitute a binding commitment of CDS.

     3.5  Reports. CDS shall submit to GEN-PROBE within thirty (30) days after
the end of each Calendar Quarter during the Term, a written report of sales
activity during the previous quarter. CDS shall also provide on a semi-annual
basis a description of all marketing activities undertaken by CDS in the
Territory during the previous half year. CDS will, from time to time, provide
GEN-PROBE with additional relevant information which may include advice as to
the market potential for the Products in each country, sales trends, changes in
competitive environment, regulatory climate and such other similar matters as
may be within its knowledge.

                                   ARTICLE IV
                           PRICING AND PAYMENT TERMS

     4.1  Pricing. The price payable by CDS for each Product sold hereunder
shall be the Sale Price for such product in effect on the date on which CDS
submits its purchase order for such Product. The Sale Prices initially in effect
are as set forth in Exhibit A. All prices are stated in U.S. dollars F.O.B. San
Diego, California and do not include freight, insurance or sales tax, use tax,
excise tax, VAT, export and import duties, imposts or any similar tax or
assessments of any governmental entity, all of which shall be borne solely by
CDS (other than taxes on the net income of GEN-PROBE). If a resale certificate
or other certificate or document of exemption is required in order to exempt the
transactions described in this Agreement from sales, value-added or use tax
liability, CDS or GEN-PROBE, as applicable, shall furnish to the other party
such certificate or document prior to shipment.

     4.2  Pricing Changes. For orders submitted from the date hereof until the
end of the third Performance Period, Sale Prices shall be in effect as set forth
in Exhibit A. Pricing changes, if necessary during the Term, shall be discussed
by the Parties in good faith in January of any year(s) during the Term.

     4.3  List Prices. CDS shall have the right to set list prices to end users.
GEN-PROBE agrees not to set, publish and/or distribute or supply any other
suggested end user prices of Products intended for sale in the Territory.

     4.4  Payment Terms. Invoices shall be rendered for each delivery. CDS shall
pay GEN-PROBE in U.S. dollars for the Products and for any other amounts for
which CDS is liable hereunder within forty-five (45) days of invoice date or
within thirty (30) days of delivery date, whichever is later, by wire transfer
to GEN-PROBE's bank account as specified by GEN-PROBE. Any late payments shall
bear interest, except in the event that Section 18.2 hereof is applicable, at an
annual rate of two (2) percentage points above the prime rate from time to time
quoted by Wells Fargo Bank at its principal office in San Francisco, California,
with changes in such prime rate to be effective as of the date of each such
charge. Failure to make payment when due shall constitute a breach hereof
subject to applicable provisions as.

                                      -6-
<PAGE>
to notice, cure and termination, as provided in Section 16.2(a).
Notwithstanding the above, CDS may be excused from payments under this
Agreement to the extent that Section 18.2 hereof is applicable.

                                   ARTICLE V
                               QUALITY ASSURANCE

      GEN-PROBE warrants that all Products shall meet the Quality Control
Specifications ("QC Specifications") in effect as of the commencement of the
Term. GEN-PROBE shall not materially modify any Product or any QC Specification
without the prior written consent of CDS, which shall not be unreasonably
withheld. GEN-PROBE shall provide notice of every proposed modification of a
Product or QC Specification in a manner and at a time such that CDS shall be
able to consider the impact of the proposed modification and the appropriateness
of such modification in light of regulatory requirements in the Territory.

                                   ARTICLE VI
                            DELIVERY, RISK AND TITLE

     6.1  Shipment.  All shipments are F.O.B. San Diego, California. GEN-PROBE
shall use reasonable efforts to provide Products to CDS so as to maximize their
shelf life pursuant to Exhibit C. In no case shall GEN-PROBE ship any Products
having a projected remaining shelf life of less than six (6) months, except
after consultation and with the prior written agreement of CDS. CDS shall
specify the method of shipment and insurance and GEN-PROBE shall attempt, in
good faith, to comply with such specification. If no such specification is made
or if the specification cannot be reasonably complied with, GEN-PROBE may
select the manner of shipment and insurance on behalf of CDS, but such carrier
shall not be deemed to be an agent of GEN-PROBE, nor shall GEN-PROBE have any
liability for the performance of the carrier or any delays or damage in
shipment. All shipping, transportation, insurance and similar charges shall be
the responsibility of CDS and, if paid or incurred by GEN-PROBE, shall be
promptly reimbursed by CDS to GEN-PROBE.

     6.2  Certified Quality Control Certificate.  Each shipment of a Product by
GEN-PROBE to CDS for resale or sampling to customers shall be accompanied by a
certified quality control certificate, as well as other documentation as is
necessary and appropriate for customs purposes.

     6.3  Delivery Scheduling.  Unless otherwise agreed in writing, during the
Term, GEN-PROBE will use its reasonable commercial efforts to deliver Products
ordered pursuant to Section 3.2 on the date specified in the applicable order.
If GEN-PROBE finds that it will not be able to ship the Products on the date
specified in the applicable order, GEN-PROBE shall inform CDS in writing of the
reason of the delay and a scheduled delivery date. Failing delivery on such
date, and subject to CDS's right of cancellation or rejection in the event of
undue delay, GEN-PROBE shall cause delivery as soon thereafter as practicable,
provided such order is made in accordance with the terms of this Agreement and,
provided further, that GEN-PROBE reserves the right to limit, delay or refuse
shipment if CDS is past

                                      -7-
<PAGE>
due on any payment or is otherwise in breach of this Agreement. In addition,
GEN-PROBE may be excused from delivery of Products under this Agreement to the
extent that Section 18.2 hereof is applicable.

     6.4 Title and Risk.  Title to the Products and risk of loss for the
Products shall pass to CDS upon delivery to the carrier F.O.B. San Diego,
California. CDS hereby grants to GEN-PROBE a security interest (and such
similar rights under the laws of any country) in all Products delivered
hereunder and the proceeds thereof until the purchase price therefor has been
paid in full; provided, however, that GEN-PROBE hereby releases such security
interest, except in the event that CDS shall be in breach regarding payment of
the purchase price, effective upon such payment in full, and provided further,
that such arrangements shall in no way prejudice CDS's right to sell the
Products. CDS shall execute any instruments or documents which GEN-PROBE
reasonably deems appropriate to establish and perfect said security interest
and, in any event, a copy of this Agreement may be filed at any time after
execution by CDS as a financing statement for that purpose; provided, however,
that such documents and instruments shall provide for such release as
contemplated above.

                                  ARTICLE VII
                            PACKAGING AND TRADEMARKS

     7.1 GEN-PROBE Packaging.  GEN-PROBE shall be responsible for packaging the
Products in a box with Japanese language labeling and for inserting a Japanese
language package insert. The artwork for all labeling will be provided by CDS at
no cost to GEN-PROBE. The cost of printing and using the CDS packaging will be a
component of GEN-PROBE's Sale Price.

     7.2 CDS Labeling and Packaging.  CDS will provide GEN-PROBE with a draft of
its package insert for review. GEN-PROBE will give CDS its comments or
counterdraft within fifteen (15) business days from its receipt of the official
request from CDS. CDS shall provide and bear the cost of additional labeling,
packaging and/or product literature (including translations) necessary or
appropriate to comply with the laws, regulations, industry and medical standards
and good commercial practices within the Territory. GEN-PROBE shall assist CDS,
without charge for reasonable assistance of GEN-PROBE personnel not involving
any out-of-pocket expense and not unduly interfering with such personnel's
normal business activities, and otherwise at the expense of CDS, in the
preparation of such filings as may be required under laws and regulations
throughout the Territory to effectuate and maintain registration and other
regulatory approvals of Products in the Territory. CDS will distribute Products
only with the appropriate labeling, packaging and product literature (in every
case  complete and unobscured) and only under GEN-PROBE's applicable trademarks
and trade names. GEN-PROBE shall have the right to review final labeling,
packaging and product literature and any changes thereto. GEN-PROBE will give
CDS its comments or counterdraft within fifteen (15) business days from its
receipt of the official request from CDS. In no event shall CDS make any
material statement with respect to any Product in any insert, labeling,
packaging or literature which is different than statements made by GEN-PROBE
with respect to such Product.

                                      -8-

<PAGE>
     7.3 Trademark License.  GEN-PROBE hereby grants to CDS the royalty-free,
non-exclusive, non-assignable, and non-sublicensable right to use GEN-PROBE's
trademarks and trade names in connection with the promotion and distribution of
the Products during the Term, it being expressly understood that CDS shall use
GEN-PROBE's trademarks and trade names during the Term for the sole purpose of
distributing the Products hereunder and shall promptly discontinue any and all
use of such trademarks or trade names upon the termination or expiration of the
Term. CDS disclaims any right to the trademarks and trade names of GEN-PROBE
other than pursuant to this license. Notwithstanding the foregoing, CDS may use
trademarks and trade names of GEN-PROBE only as approved by GEN-PROBE in writing
(which approval shall not be unreasonably withheld) other than pursuant to this
license. To the extent that CDS uses any trademark or trade name of GEN-PROBE
under this Agreement, CDS shall accompany any such use with a conspicuous
notation to the effect that such trademark or trade name is owned by Gen-Probe
Incorporated and with any other proprietary legend which GEN-PROBE reasonably
determines is necessary to protect its proprietary interest therein. CDS shall
not affix any trademark or trade name of GEN-PROBE to any product other than the
Products.

     7.4 Protection of Patents, Trademarks and Copyrights.  CDS recognizes
GEN-PROBE's right, title and interest in its patents, trademarks, trade names
and copyrights, trade secrets, and proprietary information in connection with
the Products, and CDS shall not claim any ownership right thereto inconsistent
with this Agreement. In the event any Third Party shall infringe on GEN-PROBE's
rights in its patents, trademarks, trade names or copyrights, trade secrets or
proprietary rights, CDS shall inform GEN-PROBE thereof as soon as possible and,
at GEN-PROBE's request, render reasonable assistance to GEN-PROBE in prosecuting
such claims.

     7.5 Authorized Distributor.  CDS may identify itself during the Term as an
authorized distributor of GEN-PROBE Products, but shall not use any of
GEN-PROBE's trademarks or trade names in its corporate name or in any other
manner not expressly authorized by GEN-PROBE.

                                  ARTICLE VIII
                       TECHNICAL INFORMATION AND KNOW-HOW

     8.1 Customer Support.  CDS shall be responsible for all technical support
as provided to current CDS customers and after-sales service of its customers
for the Products and shall provide such support and service at reasonable levels
acceptance to GEN-PROBE. As part of its efforts in this regard, CDS shall, at
its own cost and expense:

          (a)  Organize, train and maintain an after-sales department consisting
of a team of technicians specializing in technical maintenance, repair and
service of the Products sufficient in size to provide adequate support to
customers within the Territory; and

          (b)  Keep a record of all customer complaints, circumstances,
occurrences or conditions which have affected or could affect Product quality,
including shipment duration, storage, handling and packaging, and any other
problems, irregularities or malfunctions, including, without limitation,
technical or scientific problems which may affect the reliability of

                                      -9-

<PAGE>

the Products and/or the biological results obtained by customers. CDS shall
communicate all such matters promptly to GEN-PROBE.

     8.2  GEN-PROBE Support. During the Term, GEN-PROBE shall provide technical
support for the Products directly to CDS at the expense of GEN-PROBE, and shall
provide technical updates to CDS from time to time as and if such updates become
available. During the Term, a schedule of technical support programs by
GEN-PROBE to CDS for the next Calendar Year will be determined between the
parties by the end of third Calendar Quarter.

     8.3  Additional Training. At reasonable times, CDS, at its expense, may
send to GEN-PROBE's facility additional representatives for training relating to
the Products including theory and applications of the Products, "hands-on" use
of the Products, and analysis of competitors and competitive products.

                                   ARTICLE IX
                                   MARKETING

     9.1  Diligent Efforts. During the Term, CDS shall use diligent efforts on a
commercially reasonable basis to continuously promote and sell the Products in
the Territory. All costs and expenses of advertising, sales promotion,
workshops, seminars and convention exhibits shall be the responsibility of CDS.
CDS shall provide to GEN-PROBE for GEN-PROBE's prior review all English language
translations of promotional materials which CDS proposes to use with respect to
the Products. During the Term, GEN-PROBE shall supply, at no cost to CDS, one
set of camera ready artwork and/or color separated negatives of advertising and
promotional material used by GEN-PROBE.

     9.2  Changes in Printed Material. During the Term, Gen-PROBE shall notify
CDS, in writing, regarding any changes to any promotional material and/or
packaging warnings and/or instructions to accompany the Products and CDS's
labeling, packaging and product literature shall thereupon be appropriately
modified to conform therewith. Such notification shall be made sufficiently in
advance so as not to disrupt CDS's operations except in any cases in which
prompt action is required based on safety or efficacy concerns.

     9.3  Inquiries from Outside the Territory. CDS shall direct to GEN-PROBE
any customer/end-user inquiries and leads for delivery or use of Products
outside the Territory. GEN-PROBE may use such leads and lists without
restriction for its own marketing purposes, whether or not related to the
Products or this Agreement.

                                   ARTICLE X
                     WARRANTIES, LIABILITY AND DISCLAIMERS

     10.1 Product Warranties. GEN-PROBE MAKES NO REPRESENTATION OR WARRANTY OF
ANY KIND, EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY AS
TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE EXCEPT THAT GEN-PROBE
SHALL HAVE GOOD TITLE TO THE PRODUCTS SOLD TO CDS HEREUNDER, FREE OF LIENS OR
OTHER CLAIMS OF OTHERS, AND EXCEPT THAT THE PRODUCTS SOLD TO CDS HEREUNDER
SHALL MEET THE

                                      -10-

<PAGE>
STANDARD TECHNICAL SPECIFICATIONS THEREOF SET FORTH IN GEN-PROBE'S PRINTED
PRODUCT LITERATURE AND QC SPECIFICATIONS REFERRED TO IN ARTICLE V HEREOF;
PROVIDED, HOWEVER, THAT WITH RESPECT TO ANY PRODUCT SOLD BY CDS IN THE
TERRITORY, GEN-PROBE SHALL MAKE AVAILABLE TO CDS AND TO THE END-USER A WARRANTY
NO LESS FAVORABLE THAN ANY WARRANTY GEN-PROBE MAY BE ISSUING AT SUCH TIME WITH
RESPECT TO SUCH PRODUCT OUTSIDE THE TERRITORY. THE FOREGOING LIMITED WARRANTY
MAY BE EXPANDED ONLY TO THE EXTENT THAT GEN-PROBE SHALL LATER ISSUE A SEPARATE
SPECIFIC WRITTEN WARRANTY TO CDS.

     10.2 Limitation of Remedy. No claim based upon any alleged breach of
warranty shall be valid unless: (a) GEN-PROBE shall have received notice of such
claim in writing (i) within ninety (90) days after receipt by CDS of notice of
the alleged defect from a customer giving rise to such claim, or (ii) within two
(2) years after the date of receipt by CDS of the Product at issue, whichever is
earlier; and (b) CDS shall cooperate with GEN-PROBE in the investigation of any
such claim and shall use commercially reasonable efforts to endeavor to gain the
cooperation of the affected end-users. GEN-PROBE's warranty obligation hereunder
shall be limited to the terms of any applicable warranty made by GEN-PROBE
hereunder or the replacement or repair of defective shipments of Products, as
applicable. Defective shipments of Products (or components) will be returned to
GEN-PROBE at GEN-PROBE's expense, and Products or components replacing the
defective shipments will be sent to CDS at GEN-PROBE's expense. The foregoing
warranties shall not apply to, and GEN-PROBE shall have no liability hereunder
for, any defect or failure to the extent caused by (i) improper use,
installation, repair, alteration, mishandling or misprocessing either by CDS,
its Affiliates, their customers or end-users or (ii) hazards or accidents which
are neither attributable to GEN-PROBE nor to events prior to shipment of the
Products by GEN-PROBE, or (iii) negligence of CDS, its Affiliates or their
customers or end-users.

     10.3 Limitation of Liability. It is hereby expressly covenanted and agreed
upon by the Parties that the foregoing warranties, remedies and undertakings
are given for the benefit of CDS and its Affiliates and may not be passed on
except as expressly provided above, and that they are exclusive and are in lieu
of any warranties of merchantability, warranties of fitness for a particular
purpose or warranties or remedies of any other kind, express or implied. In no
event shall GEN-PROBE be liable to CDS or its Affiliates for any lost revenues
or profits or other special, indirect, incidental or consequential damages. CDS
shall not make any express warranty on behalf of GEN-PROBE with regard to the
Products other than as may be from time to time provided by GEN-PROBE through
any standard warranty as set forth in GEN-PROBE's end-user product literature,
as the same may be translated for local use by CDS with the prior written
approval of GEN-PROBE. Except as provided above, no warranty made by CDS to its
customers with respect to the Products shall obligate GEN-PROBE in any way.

     10.4 Recall. In the event that GEN-PROBE decides to recall, replace or take
other action with respect to any Products, it shall immediately notify CDS, in
writing, and CDS shall thereupon promptly cease sales of any units of Products
in its possession or control which are subject to the action until the course of
action to be taken has been determined. The reasonable and justifiable costs of
immediately recovering Product in the field and its

                                      -11-
<PAGE>
replacement, in any action affecting a Product, shall be home by GEN-PROBE.

     10.5 Laws, Regulations and Ethical Standards. CDS shall be responsible, at
its own expense, for compliance with all laws and regulations affecting the
sale, handling and distribution of the Products in the Territory. GEN-PROBE
shall cooperate with CDS in this regard and shall provide CDS with relevant
information available to GEN-PROBE. CDS and GEN-PROBE shall each conduct and
maintain its business in material compliance with all applicable laws,
ordinances, regulations and rules of and all governmental authorities and
regulatory bodies. CDS and GEN-PROBE shall not engage in any unfair trade
practice, including, without limitation, (i) false or misleading representations
concerning the Products, (ii) illegal "loss leader", "bait and switch" or other
misleading or deceptive advertising or (iii) any practice designed improperly to
control prices. Each Party shall promptly notify the other in writing of any
such conduct by a representative of such Party or any other distributor or
dealer, or of any complaint received by such Party alleging any such conduct.

                                   ARTICLE XI
                            CONFIDENTIAL INFORMATION

     11.1 Each Party agrees to use all Confidential Information of the other
provided to it or obtained by it pursuant to this Agreement only as contemplated
by and in furtherance of this Agreement. Each Party acknowledges the other
Party's sole rights in the Confidential Information of such other Party. Each
Party shall ensure that, without the prior written approval of the other, no
Confidential Information of the other is used for any purpose other than as set
forth herein or disclosed to any Third Party (except its duly authorized
representatives, employees and agents who need to know such information in
furtherance of this Agreement) during the Term and for four (4) years after the
end of the Term. Within thirty (30) days of the end of the Term, each Party
shall either return to the other Party or, at the request of the other Party,
destroy all Confidential Information of the other Party in its possession,
including, without limitation, all manuals covering products and any customer or
prospect lists provided by the other Party.

     11.2 Confidential Information shall not include:

          a.   Information which was generally available to the public at the
     time of disclosure, or information which becomes available to the public
     after disclosure by Disclosing Party other than through fault of the
     Receiving Party.

          b.   Information which can be shown to have been already known to the
     Receiving Party prior to its receipt from the Disclosing Party.

          c.   Information which is obtained at any time lawfully from a Third
     Party under circumstances permitting its use or disclosure to others.

          d.   Information which is developed independently by Receiving Party
     as evidenced by written records other than through knowledge of the
     Confidential Information.

                                      -12-

<PAGE>
          e.   Information required to be disclosed by the Receiving Party to
     comply with a court or administrative order provided the Receiving Party
     furnishes prompt notice (in no event less than three (3) days) to
     Disclosing Party to enable it to resist such disclosure.

     11.3. The foregoing exceptions to Confidential Information shall not
operate to exclude from Confidential Information that which (i) is merely
embraced by more general information available on a nonconfidential basis or,
(ii) consists of a combination of features, each of which may be publicly
available, but wherein the combination itself and its principle of operation
constitute Confidential Information because they are not embraced by
corresponding information which is within one of the foregoing exceptions.

                                  ARTICLE XII
                                  INFRINGEMENT

     12.1 If CDS receives a claim of a Third Party that any Product infringes a
patent, copyright or trademark or misappropriates any other right of a Third
Party in the Territory, then CDS will notify GEN-PROBE promptly in writing
within fifteen (15) days of receipt by it of such claim and give GEN-PROBE all
reasonable information, assistance and cooperation for the defense of same at
GEN-PROBE's expense. GEN-PROBE shall have the exclusive authority to evaluate,
defend such claim, except as to settlement, provided that GEN-PROBE shall
continue to inform CDS of the progress of such defense, and further provided
that GEN-PROBE shall provide CDS with all the information relating to such
defense at CDS's request. GEN-PROBE, at its own expense and option, may (i)
assume control of the settlement and/or defense of such claim, (ii) allow CDS to
do so at GEN-PROBE's expense, (iii) procure for CDS the right to continue using
and transferring the Product in question, (iv) replace or modify the Product so
that no infringement will occur, or (v) remove the Product involved from Exhibit
A and refund the price thereof as depreciated or amortized over the lifetime of
the Product as established by GEN-PROBE. Provided CDS has given GEN-PROBE
reasonable notice, assistance and cooperation, GEN-PROBE shall obtain the prior
written consent of CDS before the settlement, and GEN-PROBE will pay any damages
or settlement finally awarded on account of each claim; provided GEN-PROBE, in
the case of settlement, approves such settlement.

     12.2 Notwithstanding the foregoing, GEN-PROBE shall not be liable to CDS to
the extent any such claim is based upon (i) use of the Products in connection
with or combination with any other products, equipment, devices or software not
provided or delivered by GEN-PROBE and where such use or combination was not
otherwise approved by GEN-PROBE, (ii) modification (otherwise than as directed
or approved by GEN-PROBE pursuant to Section 10.5 or Section 12.3 hereof) of or
damage to the Products after shipment by GEN-PROBE, (iii) any use of the
Products in a manner different from that specified in GEN-PROBE's product
literature or (iv) any negligent acts of CDS. Unless otherwise permitted by
GEN-PROBE, CDS shall promptly suspend sale and distribution of any Product after
receipt of an infringement claim (and the parties shall in good faith consult as
to the possible adjustment of any applicable Minimum Purchase Commitment, if
any). GEN-PROBE's obligations hereunder shall not apply to any infringement
claim asserted after CDS has received notice alleging the infringement unless
GEN-PROBE has given CDS express written permission for such

                                      -13-

<PAGE>
continuing distribution notwithstanding the allegation of infringement.

     12.3 Notwithstanding any other provisions hereof, GEN-PROBE shall not be
liable for any claim of infringement based on CDS's use of the Products as
shipped, if GEN-PROBE has suggested to CDS modifications or changes in the
Products or their use in order to avoid such claims of infringement and
GEN-PROBE has offered to implement those modifications or changes, if such
claim of infringement would have been avoided by implementation of GEN-PROBE's
modifications or changes.

     12.4 The provisions of this Article XII are solely for CDS's and its
Affiliates' benefit and shall be in lieu of, and GEN-PROBE expressly disclaims,
any warranties of noninfringement with respect to the Products.

     12.5 CDS shall indemnify GEN-PROBE for, and hold it harmless from, any
loss, cost or expense suffered or incurred in connection with any claim, suit,
or proceeding brought against GEN-PROBE, insofar as it is based on the
modification or alteration of a Product other than by GEN-PROBE or as directed
or approved by GEN-PROBE pursuant to Section 10.5 or Section 12.3 or the
combination of a Product with any equipment, device, or software not supplied
by GEN-PROBE where such combination was not approved by GEN-PROBE.

                                  ARTICLE XIII
                          RELATIONSHIP OF THE PARTIES

     CDS acknowledges that both parties hereto are independent contractors and
that no partnership or joint venture shall be deemed to be formed under this
Agreement. CDS shall, on its own behalf, solicit orders for Products only as an
independent contractor. CDS shall, on its own behalf, solicit orders for
Products only as an independent contractor. CDS shall arrange the terms and
conditions of sale of Products, including price, independent of GEN-PROBE. CDS
shall not represent itself as a partner, joint venturer, agent, employee or
general representative of GEN-PROBE. Except as specifically provided herein,
CDS acknowledges that it shall have no right, power or authority to in any way
obligate GEN-PROBE to any contract or other obligation.

                                  ARTICLE XIV
                                INDEMNIFICATION

     14.1 CDS agrees to indemnify, defend and save harmless GEN-PROBE and its
Affiliates, and their officers, directors, agents, employees, legal
representatives, successors and assigns, and each of them, from any and all
claims, actions, suits, liabilities, judgments, losses, damages, costs,
charges, attorneys' fees and costs (hereinafter "Losses") (whether incurred in
any action between GEN-PROBE and CDS or between GEN-PROBE and any Third Party),
caused or resulting, directly or indirectly, from any acts or omissions of CDS
in connection with the Products or its related business activities (including,
without limitation, any breach by CDS of this Agreement), except to the extent
any such Losses (i) are covered under GEN-PROBE's warranty and limited
liability as set forth herein, (ii) result from any breach by GEN-PROBE of its
obligations hereunder, or (iii) result from the fault of GEN-

                                      -14-
<PAGE>
PROBE. CDS further agrees that the provisions contained in this section shall
survive the termination or expiration of this Agreement. CDS will maintain at
all times during the term of this Agreement and provide evidence to GEN-PROBE
of general operating and product liability insurance policies of a kind and in
an amount reasonably satisfactory to GEN-PROBE.

     14.2 GEN-PROBE agrees to indemnify, defend and save harmless CDS and its
Affiliates, and their officers, directors, agents, employees, legal
representatives, successors and assigns, and each of them, from any and all
Losses (whether incurred in any action between GEN-PROBE and CDS or between CDS
and any Third Party), to the extent caused or resulting, directly or
indirectly, from any acts or omissions of GEN-PROBE in connection with the
Products or its business activities relating to manufacture thereof (including,
without limitation, any breach by GEN-PROBE of this Agreement) except to the
extent any such Losses (i) result from any breach by CDS of its obligations
hereunder or (ii) result from the fault of CDS. GEN-PROBE further agrees that
the provisions contained in this section shall survive the termination of
expiration of this Agreement. GEN-PROBE will maintain at all times during the
term of this Agreement and provide evidence to CDS of general operating and
product liability insurance policies of a kind and in an amount reasonably
satisfactory to CDS.

                                   ARTICLE XV
                               EXPORT REGULATIONS

     15.1 CDs shall be responsible for and shall bear all costs of obtaining
import and export licenses and all governmental consents or authorizations with
respect to shipment of the Products into the Territory from the United States
and shall demonstrate to GEN-PROBE's satisfaction compliance with applicable
laws and regulations prior to the scheduled date for any shipment outside the
United States. CDS shall be responsible for and shall bear all costs of
clearing the Products through customs in the Territory and shall pay all
customs duties with respect thereto.

     15.2 Neither CDS nor any Affiliate thereof nor any customer thereof, as
provided in the following sentence, shall export from the country in which it
first takes possession of any Products or technical information with respect
thereto, or re-export from anywhere, any Products or technical information with
respect thereto (or a direct product thereof, including without limitation,
processes and services) unless it had first complied with, and demonstrated
compliance to GEN-PROBE's reasonable satisfaction, all applicable export
regulation, including, without limitation, those of the United States. To the
extent required and/or permitted by applicable law, CDS and its Affiliates will
make reasonable efforts to impose a like obligation upon their customers and
shall take all reasonable steps available, including legal action, to enforce
such obligation.

                                  ARTICLE XVI
                              TERM AND TERMINATION

     16.1 Term.  The term of this Agreement (the "Term") shall be from September
1, 1998 through December 31, 2002, unless earlier terminated hereunder. Not less
than one (1) year prior to the scheduled expiration of the Term, the Parties
shall commence negotiations

                                      -15-
<PAGE>
regarding a possible extension of the Term on mutually acceptable terms,
provided that, unless the parties shall have reached mutual agreement on the
terms and conditions of such an extension by the date of six (6) months prior to
the scheduled expiration of the Term, the Term shall automatically expire on the
date set forth in the first sentence of this Section 16.1.

     16.2 Early Termination.  This Agreement and/or the exclusivity of the
distributorship in Japan thereof may be terminated by either Party prior to the
scheduled expiration of the Term on written notice given to the other Party in
the event of:

         (a)  A material breach of any terms (including any payment terms) of
     this Agreement by the other Party not cured within sixty (60) days from and
     after written notice of such breach is given by the terminating party,
     except for any obligation to pay monies which shall have a thirty (30) day
     cure period unless the same is disputed in good faith, in which case, to
     avert default, the paying Party may deposit the disputed amount with a
     Third-Party escrow agent pending resolution of such Dispute and interest
     shall be payable on all disputed amounts determined to be payable at an
     annual rate of two (2) percentage points above the prime rate from time to
     time quoted by Wells Fargo Bank at its principal office in San Francisco,
     California, with changes in such prime rate to be effective as of the date
     of each such change, and further except in the event that Section 18.2
     hereof is applicable;

         (b)  The liquidation or insolvency of or the filing of bankruptcy or
     similar proceedings with respect to the other Party (provided that in the
     case of involuntary proceedings, such proceedings are not dismissed within
     sixty (60) days after filing);

         (c)  The other Party ceasing to be actively engaged in business; or

         (d)   The other Party engaging in or being charged with unethical or
     illegal practices thereby jeopardizing, in the reasonable opinion of the
     terminating Party, the reputation and good will of either Party.

16.3  Events Upon Termination or Expiration of this Agreement:

     (a)  CDS shall submit to GEN-PROBE within thirty (30) days after the
effective date of any expiration or termination of the Term a list of all
Products in CDS's inventory as of the effective date of the termination. If
GEN-PROBE terminates this Agreement pursuant to Section 16.2, GEN-PROBE may, in
its sole discretion, repurchase any or all Instruments, Products and spare parts
in the inventory of CDS or installed in the Territory at the time of termination
at the price paid by CDS for said Products and spare parts, except that, in the
case of Instruments, such price shall be reduced to the book value. If CDS
terminates this Agreement pursuant to Section 16.2, CDS shall have the right to
cause GEN-PROBE to effect the repurchases described in the preceding sentence at
the Prices described in such sentence. Upon any expiration of this Agreement,
GEN-PROBE will use reasonable efforts to obtain a commitment by the successor
distributor appointed by it to repurchase any or all Instruments, Products and
spare parts in the inventory of CDS or installed in the Territory at the time of
expiration at the price paid by CDS for said Products and spare parts, except
that, in the case of

                                      -16-

<PAGE>
     Instruments, such price shall be reduced to the book value.

         (b)  In the event of termination of this Agreement by GEN-PROBE
     pursuant to Section 16.2, GEN-PROBE may, at its option, cancel all or part
     of any scheduled but unshipped deliveries.

         (c)  All rights of CDS to sell and distribute Products hereunder shall
     be terminated except that CDS may continue to distribute in accordance with
     normal business practice and subject to the terms of this Agreement (and
     subject to GEN-PROBE's rights under Section 16.3(a)) Products previously
     shipped to it by GEN-PROBE for a period of no more than six (6) months
     following such termination or expiration.

         (d)  In the event of termination of this Agreement by GEN-PROBE
     pursuant to Section 16.2, CDS shall transfer to GEN-PROBE any and all
     Product registrations secured by CDS. GEN-PROBE agrees to reimburse CDS for
     the reasonable costs of transferring such registrations.

         (e)  CDS shall provide to GEN-PROBE a list of all current CDS customers
     for the Products.

     16.4  Continuing Obligations. Except as otherwise expressly specifically
provided herein, the expiration or termination of this Agreement shall not
release either Party from any liability of obligation arising prior to the date
of such expiration or termination. The obligations of the Parties under Article
XI, Article XIV, and Article XVII shall survive termination.

     16.5  Goodwill. Upon the expiration or termination of this Agreement, CDS
shall not under any circumstances be entitled to compensation or damages of any
kind, whether on account of the loss by CDS or present or prospective sales,
investments, compensation or goodwill. CDS, for itself and on behalf of each of
its employees, agents and representatives, hereby waives any right which may be
granted to it or them under the laws and regulations of the Territory,
including, without limitation, any claim for compensation or indemnification (i)
for its loss of business or goodwill, (ii) based on unjust enrichment to
GEN-PROBE and (iii) with respect to any damage incurred by it or by them as a
result of termination of its rights hereunder. CDS hereby agrees to indemnify
and hold GEN-PROBE harmless from and against any and all claims, costs, damages
and liabilities whatsoever asserted by any employee, agent or representative of
CDS under any applicable termination, labor, social security or other similar
laws or regulations of the Territory.

     Upon the expiration or termination of this Agreement by CDS pursuant to
Section 16.2 due to a material breach by GEN-PROBE, GEN-PROBE shall not under
any circumstances be entitled to compensation or damages of any kind (except as
to such amounts as may be then due and owing for Products previously shipped to
CDS), whether on account of the loss by GEN-PROBE of present or prospective
sales, investments, compensation or goodwill. GEN-PROBE, for itself and on
behalf of each of its employees, agents and representatives, hereby waives any
right which may be granted to it or them under the laws and regulations of the
Territory and the United States of America, including, without limitation, any
claim for

                                      -17-

<PAGE>

compensation or indemnification (i) for its loss of business or goodwill, (ii)
based on unjust enrichment to CDS and (iii) with respect to any damage incurred
by it or by them as a result of termination of its rights hereunder. GEN-PROBE
hereby agrees to indemnify and hold CDS harmless from and against any and all
claims, costs, damages and liabilities whatsoever asserted by any employee,
agent or representative of GEN-PROBE under any applicable termination, labor,
social security or other similar laws or regulations of the Territory and the
United States of America.

                                  ARTICLE XVII
                               DISPUTE RESOLUTION

     17.1  Disputes. All disputes regarding this Agreement shall be resolved in
           --------
the following manner:

               (a)  The CEO's of CDS and GEN-PROBE shall meet in person to
discuss each Party's view and to explain the basis for their respective
positions in the Dispute and in good faith shall attempt to resolve such
Dispute between themselves.

               (b)  If such CEO's cannot promptly resolve such Dispute, then
the CEO's shall endeavor in good faith to establish a mutually acceptable
method to resolve such Dispute, and such Dispute shall be resolved in
accordance with such method if so established, or by mediation if no
alternative method is established, or if such alternative method does not
resolve the Dispute. In the event that the Dispute cannot be resolved through
mediation, the matter shall be referred to arbitration as set forth in Section
17.2 below.

     17.2  Arbitration.  Subject to the provisions of Section 17.1, any
           -----------
controversy, claim or Dispute existing out of and/or relating to this
Agreement, or the breach thereof, shall be finally resolved by binding
arbitration in New York, New York in accordance with the rules of International
Chamber of Commerce and any judgment upon the award rendered by arbitration may
be entered in any Court having jurisdiction. Any arbitration award shall also
include, but shall not be limited to, any and all court or arbitration costs,
attorney's fees and any other costs or charges reasonably necessary to
adjudicate the controversy, in addition to any and all damages deemed fair by
the Arbitrator(s). Nothing contained herein shall deprive any party of his or
her right to obtain injunctive or other equitable relief.

                                 ARTICLE XVIII
                               GENERAL PROVISIONS

     18.1  Assignment.  Neither Party to this Agreement shall have the right to
           ----------
assign, delegate, mortgage, pledge, hypothecate, sublicense or otherwise
transfer any rights or obligations under this Agreement without the written
consent of the other Party, which shall not be unreasonably withheld. Any such
purported transfer without such consent shall be deemed void and without
effect. For purposes of this Agreement, "assignment" shall include (i) the
transfer of substantially all of the assets of a Party, even if this Agreement
is specifically excluded from such transfer and (ii) any change in the ultimate
beneficial control of a Party. Notwithstanding the foregoing, either Party may
assign and transfer this Agreement, including all its rights and obligations
hereunder, to any Affiliate of such Party, provided that such

                                      -18-
<PAGE>

assignment shall not relieve the assigning Party of its obligations hereunder.
In addition, GEN-PROBE may assign or transfer any rights to any of its
Affiliate to receive payments hereunder upon prior written approval by CDS.

     18.2  Force Majeure.  Each of the Parties hereto shall be excused from the
           ----- -------
performance of its obligations hereunder in the event performance of this
Agreement is prevented by force majeure and such excuse shall continue as long
as the condition constituting such force majeure continues, plus thirty (30)
days after the termination of such condition. For purposes of this Agreement,
force majeure is defined as follows:

               Causes beyond the control of CDS or GEN-PROBE,
          including acts of God, war, any regulations, acts, rules, orders,
          proclamations, requirements or laws of any government, civil
          commotion, strike, lockout or other industrial dispute, destruction of
          production facilities or material by fire, water, earthquake or storm,
          plant breakdown or failure of equipment, inability to obtain equipment
          and/or supplies, epidemics and failure of public utilities or common
          carriers.

     18.3  Waiver.  A waiver by either Party of a breach or violation of any
           ------
provision of this Agreement will not constitute or be construed as a waiver of
any subsequent breach or violation of that provision or as a waiver of any
breach or violation of any other provision of this Agreement.

     18.4  Governing Law.  This Agreement will be construed and governed in
           --------- ---
accordance with the laws of the State of New York.

     18.5  Entire Agreement.  This Agreement embodies the entire understanding
           ------ ---------
between the Parties relating to the subject matter hereof and supersedes all
prior understandings and agreements, whether written or oral.

     18.6  Severability.  Any of the provisions of this Agreement which are
           ------------
determined to be invalid or unenforceable in any jurisdiction will be
ineffective to the extent of such invalidity or unenforceability in such
jurisdiction, without rendering invalid or unenforceable the remaining
provisions hereof or affecting the validity or unenforceability of any of the
terms of this Agreement in any other jurisdiction.

     18.7  Headings.  The headings and captions used in this Agreement are for
           --------
convenience of reference only and will not affect its construction or
interpretation.

     18.8  Notices.  All notice or other communication in connection with this
           -------
Agreement must be in writing sent by certified or registered mail, return
receipt requested, addressed as follows:

                                      -19-

<PAGE>
          If to GEN-PROBE:

                 Henry L. Nordhoff, President & CEO
                 Gen-Probe Incorporated
                 10210 Genetic Center Drive
                 San Diego, California 92121-4362
                 cc:  General Counsel

          If to CDS:

                 Yoshihito Koike, President
                 Chugai Diagnostics Science Co., Ltd.
                 41-8, Takada 3-Chome, Toshima-ku
                 Tokyo 171-8545, Japan

or such other person or persons at such address or addresses as may be
designated by written notice to the other parties hereunder.

          18.9   Changes/Modifications.  This Agreement may not be changed or
modified except in a writing signed by duly authorized representatives of the
Parties.

          18.10  Conflicting Documents.  Such terms and conditions of CDS's
orders or other sales documents as may be in conflict in whole or in part with
the provisions of this Agreement shall be of no force or effect whatsoever and
the provisions of this Agreement shall be controlling in any such instance. It
is the intention of both Parties hereto that the acceptance, even in writing,
of any such purchase or sales document does not constitute a modification or
amendment of or addition to the terms of this Agreement unless accompanied by a
typed letter Agreement conspicuously entitled "Amendment of Agreement" which
begins with a proposal to amend the Agreement and specifies exactly each change
to be made and which is signed by an authorized officer of both Parties.

          18.11  No Third Party Benefits.  Nothing in this Agreement, express
or implied, is intended to confer on any person other than the Parties hereto
or their permitted assigns, any benefits, rights or remedies.

          18.12  Registration.  In the event that this Agreement is required to
be registered with any governmental authority in the Territory, CDS shall cause
such registration to be made and shall bear any expense or tax payable in
respect thereof.

          18.13  English Language.  The official text of this Agreement shall
be in the English language, and such English text shall be controlling in all
respects, notwithstanding any translation hereof required under the laws and
regulations of any country in the Territory. The parties undertake to use the
English language in respect of all documents and communications contemplated
herein, except where another language must be used under the laws and
regulations of any country in the Territory. The parties undertake to use the
English language in respect of all documents and communications contemplated
herein, except where another language must be used under the laws and
regulations of any country in the Territory. In any such case, a certified
English translation shall be supplied to the other Party by the Party using
such documents or making such communication.

                                      -20-
<PAGE>

          18.14  Attorneys' Fees.  If either party hereto commences an
arbitration or other action against the other Party to enforce any of the terms
hereof or because of the breach by such other Party of any of the terms hereof,
the prevailing Party shall be entitled, in addition to any other relief
granted, to all actual out-of-pocket costs and expenses incurred by such
prevailing Party in connection with such action, including, without limitation,
all reasonable attorneys' fees and a right to such costs and expenses as shall
be deemed to have accrued upon the commencement of such action and shall be
enforceable whether or not such action is prosecuted to judgment.

          18.15.  Counterparts.  This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

          IN WITNESS WHEREOF, the Parties hereto have affixed their authorized
signatures.

GEN-PROBE INCORPORATED                            CHUGAI DIAGNOSTICS SCIENCE
                                                       CO., LTD.

By: /s/ Henry L. Nordhoff                         By: /s/ Yoshihito Koike
    ---------------------                             -------------------
       Henry L. Nordhoff                                Yoshihito Koike
    President & Chief Executive Officer                    President

Date: 28-AUGUST-98                                Date: 28. AUG-98
      -------------------                               -----------------

[APPROVED BY LEGAL DEPT. STAMP]

                                      -21-
<PAGE>

                                   EXHIBIT A

                             PRODUCT AND PRICE LIST
<PAGE>

<Table>

                                   EXHIBIT A                                                                         Page 1

<Caption>

<S>       <C>                                                         <C>                  <C>                   <C>
-----------------------------------------------------------------------------------------------------------------------------------
                                                                                              PRICE
-----------------------------------------------------------------------------------------------------------------------------------
Cat. No.                PRODUCT DESCRIPTION                            Sept. 1, 1998        Jan. 1, 1999         Jan. 1, 2000

-----------------------------------------------------------------------------------------------------------------------------------
  1591J       MYCOPLASMA T.C. H3                                           [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
  1791J       DETECTION REAGENT KIT                                        [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
  1792J       PACE2 CHLAMYDIA TRACHOMATIS                                  [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
  1793J       PACE2 NEISSERIA GONORRHOEAE                                  [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
  3300J       FEMALE COLLECTION KITS                                       [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
  3275J       MALE COLLECTION KITS                                         [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2930       FAST EXPRESS REAGENT KIT                                     [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2325       STD PROFICIENCY PANEL, 3 VIALS/BOX                           [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   3548       PACE2 C. TRACHOMATIS PROBE COMPETITION ASSAY                 [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   3549       PACE2 N. GONORRHOEAE PROBE COMPETITION ASSAY                 [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   3905       PACE2 FOR C. TRACHOMATIS & N. GONORRHOEAE                    [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2800       ACCUPROBE GENERIC REAGENT KIT                                [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2810       ACCUPROBE CAMPYLOBACTER                                      [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2815       ACCUPROBE ENTEROCOCCUS                                       [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2820       ACCUPROBE GROUP B STREPTOCOCCUS                              [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2825       ACCUPROBE HAEMOPHILUS INFLUENZAE                             [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2830       ACCUPROBE NEISSERIA GONORRHOEAE                              [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2835       ACCUPROBE MYCOBACTERIUM AVIUM                                [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2840       ACCUPROBE M. INTRACELLULARE                                  [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
  2845J       ACCUPROBE M. AVIUM COMPLEX                                   [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2850       ACCUPROBE MYCOBACTERIUM GORDONAE                             [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2855       ACCUPROBE MYCOBACTERIUM KANSASII                             [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
  2860J       ACCUPROBE M. TBERCULOSIS COMPLEX                             [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2865       ACCUPROBE STREPTOCOCCUS PNEUMONIAE                           [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2875       ACCUPROBE STREPTOCOCCUS AUREUS                               [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2890       ACCUPROBE BLASTOMYCES DERMATITIDIS                           [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2895       ACCUPROBE COCCIDIOIDES IMMITIS                               [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2910       ACCUPROBE HISTOPLASMA CAPSULATUM                             [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2920       ACCUPROBE LISTERIA MONOCYTOGENES                             [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   2925       ACCUPROBE GROUP A STREPTOCOCCUS                              [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
   3765       ACCUPROBE GROUP A STREP I.D. TEST                            [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
  3943J       CULTURE ID REAGENT, MAD, CHUGAI                              [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
  3944J       CULTURE ID REAGENT, MTB, CHUGAI                              [***]                [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
</Table>

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>
<Table>                                                       EXHIBIT A
                                                                                                                             Page 2

<S>       <C>                                                              <C>                 <C>                <C>
                                                                                                PRICE
Cat.                                                                       ----------------------------------------------------
No.       PRODUCT DESCRIPTION                                              Sept. 1, 1998       Jan. 1, 1999       Jan. 1, 2000
-------------------------------------------------------------------------------------------------------------------------------
1002J     AMPLIFIED M. TUBERCULOSIS DIRECT                                        [***]              [***]              [***]
1011J     BULK MTD, CHUGAI (300TESTS)                                             [***]              [***]              [***]
3890      GROUP A STREPTOCOCCUS DIRECT                                            [***]              [***]              [***]
1012      AMPLIFIED CHLAMYDIA TRACHOMATIS                                         [***]              [***]              [***]
1015      SWAB PROCESS, AMPLIFIED CT                                              [***]              [***]              [***]
1016      URINE PROCESS, AMPLIFIED CT                                             [***]              [***]              [***]
1018      AMPLIFIED MALE COLLECTION SWAB                                          [***]              [***]              [***]
2900      AccuLDR LUMINOMETER                                                     [***]              [***]              [***]
3100J     LEADER 50                                                               [***]              [***]              [***]
3100iJ    LEADER 50i                                                              [***]              [***]              [***]
3200IJ    leader 450i                                                             [***]              [***]              [***]
2775      GEN-PROBE HEAT BATH (20 tube capacity)                                  [***]              [***]              [***]
4006      GEN-PROBE HEAT BATH (50 tube capacity)                                  [***]              [***]              [***]
4027      SONICATOR RACK (50 holes)                                               [***]              [***]              [***]
2775A     HEATING BLOCK INSERT (20 tube capacity)                                 [***]              [***]              [***]
1714      BOTTLE TOP DISPENSER (2ml)                                              [***]              [***]              [***]
3078      BOTTLE TOP DISPENSER (5ml)                                              [***]              [***]              [***]
2113      EPPENDORF REPEAT PIPETTOR                                               [***]              [***]              [***]
1639J     PACE MAGNETIC SEPARATION UNIT (80 tube capacity)                        [***]              [***]              [***]
2065J     PACE REACTION TUBES (120/box)                                           [***]              [***]              [***]
2085      PACE SEALING CARDS (35/pack)                                            [***]              [***]              [***]
1847      LEADER PRINTER PAPER (1 roll/pack)                                      [***]              [***]              [***]
3919      WASH BOTTLE & CAP ASSEMBLY (200 ml capacity)                            [***]              [***]              [***]
4085      PLUGGED PIPETTE TIPS (175fEL-1 case, 6 boxes/case, 120/box)             [***]              [***]              [***]
3994      50-WELL STRIP RACK SYSTEM (50 tubes)                                    [***]              [***]              [***]
4008      BLUE SNAP CAPS (150/package)                                            [***]              [***]              [***]
2440      POLYPROPYLENE TUBES (250 tubes/package)                                 [***]              [***]              [***]
2618      TRITIUM STANDARD                                                        [***]              [***]              [***]
4224      PLUGGED PIPETTE TIPS, EXT, LENGTH 250fEL(6 boxes/case)                  [***]              [***]              [***]
3772      SONICATOR, 14 TUBE                                                      [***]              [***]              [***]
4033      MULTIPROBE 104                                                          [***]              [***]              [***]
4034      MULTIPROBE 204                                                          [***]              [***]              [***]
</Table>

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>
                                   EXHIBIT A
                                                                          Page 3

<Table>
<Caption>

 Cat.                                                          PRICE
  No.         PRODUCT DESCRIPTION         Sept. 1, 1998     Jan. 1,1999    Jan. 1, 2000
---------------------------------------------------------------------------------------
<S>       <C>                                    <C>             <C>            <C>
NA0002    T7 PROMOTOR PRIMER                     [***]           [***]           [***]
---------------------------------------------------------------------------------------
NA0003    NON-T7 PRIMER                          [***]           [***]           [***]
---------------------------------------------------------------------------------------
NA0007    DNA, AE PROBE                          [***]           [***]           [***]
---------------------------------------------------------------------------------------
NA0137    DNA, no RXL, no AE                     [***]           [***]           [***]
---------------------------------------------------------------------------------------
B10050    RT, Boehringer-Mannheim                [***]           [***]           [***]
---------------------------------------------------------------------------------------
B10014    T7 Life Technologies Inc.              [***]           [***]           [***]
---------------------------------------------------------------------------------------
PR0005    OIL, SILICONE                          [***]           [***]           [***]
---------------------------------------------------------------------------------------
CH0010    rATP                                   [***]           [***]           [***]
---------------------------------------------------------------------------------------
CH0011    rCTP                                   [***]           [***]           [***]
---------------------------------------------------------------------------------------
CH0012    rGTP                                   [***]           [***]           [***]
---------------------------------------------------------------------------------------
CH0013    rUTP                                   [***]           [***]           [***]
---------------------------------------------------------------------------------------
CH0166    dATP                                   [***]           [***]           [***]
---------------------------------------------------------------------------------------
CH0167    dCTP                                   [***]           [***]           [***]
---------------------------------------------------------------------------------------
CH0168    dGTP                                   [***]           [***]           [***]
---------------------------------------------------------------------------------------
CH0169    dTTP                                   [***]           [***]           [***]
---------------------------------------------------------------------------------------
LR0139J   UNLABELED ENZYME                       [***]           [***]           [***]
---------------------------------------------------------------------------------------
LR0037    HYBR. NEG. CONTROL (QC use)            [***]           [***]           [***]
---------------------------------------------------------------------------------------
SA0001    LINKER RXL                             [***]           [***]           [***]
---------------------------------------------------------------------------------------
LR0038    HYBR POS. CONTROL (QC use)             [***]           [***]           [***]
---------------------------------------------------------------------------------------
NA0048    DNA Mav A0190B                         [***]           [***]           [***]
---------------------------------------------------------------------------------------
NA0045    DNA Mav A0182F, AE                     [***]           [***]           [***]
---------------------------------------------------------------------------------------
NA0047    DNA Min A0182, AE                      [***]           [***]           [***]
---------------------------------------------------------------------------------------
LR0019    MTD NEG. CONTROL                       [***]           [***]           [***]
---------------------------------------------------------------------------------------
LR0030    MTD POS. CONTROL                       [***]           [***]           [***]
---------------------------------------------------------------------------------------
301022    TMA KIT (CML)                          [***]           [***]           [***]
---------------------------------------------------------------------------------------
301024    ANALYTE SPECIFIC KIT (CML)             [***]           [***]           [***]
---------------------------------------------------------------------------------------
301023    HPA KIT (CML)                          [***]           [***]           [***]
---------------------------------------------------------------------------------------

---------------------------------------------------------------------------------------

</TABLE>

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
                                   EXHIBIT B

                          MINIMUM PURCHASE COMMITMENT
<PAGE>
     CALENDAR PERIOD                         MINIMUM PURCHASE
     ---------------                         ----------------
                                              (DOLLAR VALUE)

                                     [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
                                   EXHIBIT C

                                SHELF LIFE PLAN
<PAGE>
                                   GEN-PROBE
                   RECOMMENDED MINIMUM DATING SHIPPING LEVELS
--------------------------------------------------------------------------------
                                                     Minimum Dating (Months)

Cat. #         PRODUCT NAME                                    Japan
--------------------------------------------------------------------------------
 1001     Amplified MTD                                        [***]
--------------------------------------------------------------------------------
 1012     Amplified Chlamydia trachomatis                      [***]
--------------------------------------------------------------------------------
 1591     MTC III                                              [***]
--------------------------------------------------------------------------------
 1791     Detection Reagents                                   [***]
--------------------------------------------------------------------------------
 1792     PACE 2 Chlaydia trachomatis                          [***]
--------------------------------------------------------------------------------
 1793     PACE 2 Neisseria gonorrhoeae                         [***]
--------------------------------------------------------------------------------
 2325     STD Proficiency Panel                                [***]
--------------------------------------------------------------------------------
 2700     HIV Gag 1/Gag 2                                      [***]
--------------------------------------------------------------------------------
 2735     HIV Gag 3/Gag 4                                      [***]
--------------------------------------------------------------------------------
 2800     AccuProbe Generic Reagent Kit                        [***]
--------------------------------------------------------------------------------
 2810     AccuProbe Campylobacter                              [***]
--------------------------------------------------------------------------------
 2815     AccuProbe Entercococcus                              [***]
--------------------------------------------------------------------------------
 2820     AccuProbe Group B Strep                              [***]
--------------------------------------------------------------------------------
 2825     AccuProbe Haemophilus influenzae                     [***]
--------------------------------------------------------------------------------
 2830     AccuProbe Neisseria gonorrhoeae                      [***]
--------------------------------------------------------------------------------
 2835     AccuProbe Mycobacterium avium                        [***]
--------------------------------------------------------------------------------
 2840     AccuProbe Mycobacterium intracellulare               [***]
--------------------------------------------------------------------------------
 2845     AccuProbe Mycobacterium avium Complex                [***]
--------------------------------------------------------------------------------
 2850     AccuProbe Mycobacterium gordonae                     [***]
--------------------------------------------------------------------------------
 2855     AccuProbe Mycobacterium kansasii                     [***]
--------------------------------------------------------------------------------
 2860     AccuProbe M. tuberculosis Complex                    [***]
--------------------------------------------------------------------------------
 2865     AccuProbe Strepococcus pneumoniae                    [***]
--------------------------------------------------------------------------------
 2875     AccuProbe Staphylococcus aureus                      [***]
--------------------------------------------------------------------------------
 2890     AccuProbe Blastomyces dermatitidis                   [***]
--------------------------------------------------------------------------------
 2895     AccuProbe Coccidioides immitis                       [***]
--------------------------------------------------------------------------------
 2910     AccuProbe Histoplasma capsulatum                     [***]
--------------------------------------------------------------------------------
 2920     AccuProbe Listeria monocytogenes                     [***]
--------------------------------------------------------------------------------
 2925     AccuProbe Group A Strep                              [***]
--------------------------------------------------------------------------------
 2930     Fast Express Reagent                                 [***]
--------------------------------------------------------------------------------
 3275     Male Collection Kit                                  [***]
--------------------------------------------------------------------------------
 3300     Female Collection Kit                                [***]
--------------------------------------------------------------------------------
 3548     PCA Chlamydia trachomatis                            [***]
--------------------------------------------------------------------------------
 3549     PCA Nesseria gonorrhoeae                             [***]
--------------------------------------------------------------------------------
 3765     AccuPACE Group A Strep                               [***]
--------------------------------------------------------------------------------
 3770     Todd Hewitt Broth Tubes                              [***]
--------------------------------------------------------------------------------
 3890     Group A Strep Direct                                 [***]
--------------------------------------------------------------------------------
 3905     PACE 2C Combination Assay (Ct/Ng)                    [***]
--------------------------------------------------------------------------------
 4009     GAS Collection & Transport                           [***]
--------------------------------------------------------------------------------
LR0019    Amplification Negative Control                       [***]
--------------------------------------------------------------------------------
LR0030    Amplification Positive Control                       [***]
--------------------------------------------------------------------------------
***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]